

Curriculum Vitae contenente l'elenco dei titoli presentati dalla dott.ssa Mirella Salvatore, congiuntamente alla domanda di partecipazione a procedura pubblica selettiva, comparativa, per titoli e colloquio, ai sensi dell'art. 11 del Regolamento di organizzazione e funzionamento dell'Istituto Superiore di Sanità per la NOMINA DEL DIRETTORE DEL CENTRO NAZIONALE PER LA SALUTE GLOBALE dell'Istituto Superiore di Sanità – Codice concorso: DIRETTORE CNSG 2025 01, Decreto Ufficiale n. 10-2025.

La sottoscritta dichiara di essere in possesso dei requisiti richiesti dall'Art. 2 punto 1 e 2 in quanto

1. Professore ed esperta italiana di comprovata esperienza scientifica internazionale come dimostrato dai titoli indicati di seguito;
2. Di avere una ottima conoscenza della lingua Inglese;
3. Di essere possesso di una laurea magistrale;
4. Dichiara, inoltre, di essere conforme a quanto richiesto dall'art. 2 punto 3.e specificamente:
 - a. non essere stata esclusa dall'elettorato politico attivo, b. di non essere stata destituita o dispensata dall'impiego presso una pubblica amministrazione per persistente insufficiente rendimento; c) di non essere stata dichiarata decaduta da un altro impiego pubblico per aver conseguito l'impiego stesso mediante la produzione di documenti falsi o viziati da invalidità insanabile; d) di non rientrare nei casi previsti dagli artt. 3 e 4 del D. Lgs. 8 aprile 2013 n. 39.

SOMMARIO DELLA FORMAZIONE E DELLE ATTIVITÀ PROFESSIONALI

Sono un medico-ricercatore con un interesse di lunga data per le malattie infettive emergenti. La mia doppia formazione professionale, sia in Italia che negli Stati Uniti, ha avuto un impatto significativo sulla mia ricerca e sulle mie interazioni professionali nei diversi contesti.

Ho conseguito la laurea in Medicina e Chirurgia con lode presso l'Università Cattolica di Roma, in Italia, e ho completato una fellowship in Endocrinologia. Dopo aver appreso dei casi di ormoni della crescita contaminati da prioni, sono rimasto affascinato da questi agenti e mi sono unito al gruppo del Professor Maurizio Pocchiari prima presso l'Università Cattolica, e successivamente all'Istituto Superiore di Sanità per studiare potenziali approcci terapeutici e fattori genetici predisponenti a queste malattie.

Nel 1996, mi sono trasferita negli Stati Uniti per proseguire la mia ricerca, completando un post-dottorato in Neurovirologia presso l'Università della California, Irvine, nel laboratorio di Ian Lipkin ("The Virus Hunter"), dove ho studiato il Borna Disease Virus, un virus animale coinvolto in disturbi psichiatrici nell'uomo. Nel 1998 mi sono trasferita al Mount Sinai School of Medicine a New York per lavorare sull'influenza pandemica nel laboratorio di Adolfo Garcia-Sastre. Al Mount Sinai ho anche completato la Specializzazione in Medicina Interna e la Fellowship in Malattie Infettive.

La formazione medica al Mount Sinai è stata fondamentale per comprendere le disuguaglianze sanitarie, e sottolineare l'importanza delle credenze culturali e personali nel trattamento delle malattie. Ho trattato pazienti ad alto reddito e veterani, e ho effettuato rotazioni in un ospedale cittadino che serve immigrati senza assicurazione provenienti da Asia, India e Sud America, con malattie rare negli Stati Uniti. Ho lavorato come 'visiting doctor' nelle strutture per persone con HIV e negli homeless shelters e condotto ricerche nei programmi di needle exchange per persone che usano oppioidi. Queste diverse esperienze mi hanno fornito la possibilità di toccare con mano e capire l'importanza di aspetti importanti di salute globale. In aggiunta la mia esperienza clinica e di ricerca in malattie infettive evidenzia giornalmente l'importanza di "One Health", mostrando come il riscaldamento globale e l'abuso di antibiotici stiano cambiando la distribuzione e frequenza delle malattie.

Nel 2009 sono entrato a far parte di Weill Cornell Medicine prima come Professore Assistente e successivamente Professore Associato di Medicina e Professore Associato di Salute delle Popolazioni. A Cornell ho proseguito la mia attività di ricerca sulle risposte dell'ospite all'influenza, e sullo sviluppo di vaccini per l'influenza che potessero essere somministrati per via mucosale. Durante la pandemia di COVID-19, ho seguito pazienti con covid di diversa severità e mi sono concentrato sull'identificazione delle risposte dell'ospite come marcatori degli esiti della malattia. Sono stata il principale investigatore

a Cornell e membro del comitato direttivo di PRESCO (Predictors of Severe COVID-19 Outcomes), un consorzio multi-istituzionale che raccoglie dati clinici e campioni di pazienti COVID-19 per lo sviluppo di strumenti predittivi di long covid. Il mio interesse attuale è sui meccanismi di persistenza dell'influenza and SARS Co-V2 nei pazienti immunocompromessi con malattie ematologiche e l'acquisizione su resistenza alle terapie virali in questi pazienti. Il mio lavoro mi ha portato a pubblicare su riviste di grande impatto scientifico, tra cui *Nature Communications*, *Nature Immunology*, *Cell Reports Medicine*, *Life Science Alliance*, *Frontiers in Immunology* e *Open Forum in Infectious Diseases*.

Oltre alla ricerca, ho svolto **attività clinica** nei reparti in malattie infettive, e presso la Vincent P. Dole Clinic, un centro integrato per il trattamento dei disturbi da uso di oppioidi che fornisce anche cure mediche e psichiatriche. **Ho insegnato** sia a specializzandi che a studenti di medicina e sono stato Direttore del Corso per la serie di seminari "Community and Public Health Research Round" a Weill Cornell Medicine (2010-2014).

Negli anni ho sviluppato anche **solide capacità manageriali** nelle attività di ricerca di laboratorio e nella ricerca clinica. Ho ottenuto finanziamenti per la ricerca di base e traslazionale, che mi hanno permesso di gestire personale tecnico, postdoc, studenti e di collaborare con numerosi gruppi di ricerca. Ho anche ottenuto finanziamenti per studi di ricerca clinica e partecipato ad attività regolatorie in questo campo. Inoltre, ho esperienza manageriale nell'ambito clinico come Direttore Medico della Clinica di Malattie Infettive e Medicina del Viaggio presso Weill Cornell Medicine.

Ho anche esperienze manageriali in società professionali sia a livello locale - sono il futuro presidente della Società di Malattie Infettive di New York- che nazionale e Internazionale.

Sono stata recentemente selezionata dalla Infectious Diseases Society of America per un Corso di formazione manageriale "Community of Leaders" in malattie infettive.

Inoltre, ho servito come revisore di grant per il NIH e come editore associato di riviste scientifiche.

La mia vasta esperienza, sia in Italia che a livello internazionale, mi rende particolarmente adatto per il ruolo di **Direttore del Centro Nazionale per la Salute Globale** dell'Istituto Superiore di Sanità. Sarebbe un onore poter contribuire al successo di questa importante istituzione.

CURRICULUM VITAE

A. DATI PERSONALI

Nome **Mirella Salvatore**
Telefono:
Indirizzo:
E-mail - Personale: mirella.salvatore@gmail.com
Data 6 Febbraio 2025
Firma 

Mirella Salvatore

B. ISTRUZIONE

Titolo di studio	Nome dell'Istituzione, sito	Data
Diploma di Maturita'	Liceo Scientifico, Nardo' (LE), Italia	1980
Laurea in Medicina e Chirurgia, <i>summa cum laude</i>	Universita' Cattolica Del Sacro Cuore, Roma, Italia	1986
Laurea in Medicina e chirurgia	ECFMG USMLE Certificato 0-592-692-8 (USA)	2001

C. FORMAZIONE POST-LAUREA

Titolo	Nome e località dell' Istituzione	Data
Specializzazione, Diabetologia and Malattie del Ricambio <i>70/70 cum laude</i>	Universita' Cattolica Del Sacro Cuore, Roma, Italia	1986-89
Specializzazione, Endocrinologia <i>70/70 cum laude</i>	Il Universita' di Roma "Tor Vergata", Roma, Italia	1989-92
Ricercatore post-dottorato, Neurovirologia	Universita' della California Irvine, Irvine, CA, USA Laboratorio di Ian Lipkin	1996-98
Ricercatore post-dottorato, Virologia	Mount Sinai School of Medicine, New York, NY, USA, Laboratorio di Adolfo Garcia-Sastre	1998-01
Specializzazione, Malattie Infettive	Mount Sinai School of Medicine, New York, NY, USA	2001-04
Specializzazione, Medicina Interna	Mount Sinai School of Medicine, New York, NY, USA	2004-06
Diploma in Malattie dei Viaggi	International Society of Travel Medicine	2011
Diploma in Ricerca Clinica e Translazionale	Weill Cornell Medicine, New York, NY, USA	2024

D. ESPERIENZE PROFESSIONALI

Posizioni Professionali Accademiche e di Ricerca

Titolo	Nome e località dell' Istituzione	Data
Associato di Ricerca Clinica	Istituto Servier, Parigi, Francia	1991-92
Ricercatore a contratto, Virologia	Istituto Superiore di Sanita' Roma, Italia	1992-95

Associato di Ricerca in Medicina	Mount Sinai School of Medicine, New York, NY, USA	2006-08
Professore Assistente (Aggiunto) di Medicina	Mount Sinai School of Medicine, New York, USA	2008-16
Professore Assistente di Medicina	Weill Cornell Medicine, New York, USA	2008-22
Professore Assistente di Salute Pubblica	Weill Cornell Medicine, New York, USA	2008-15
Professore Associato di Scienza della Salute delle Popolazioni	Weill Cornell Medicine, New York, USA	2015-22
Professore Associato di Medicina	Weill Cornell Medicine, New York, USA	2022-24
Professore Associato di Scienza della Salute delle Popolazioni	Weill Cornell Medicine, New York, USA	2022-24
Consulente Senior di Ricerca Clinica	Audax Medical Inc, MA, USA	2024-

Incarichi Clinici e Ospedalieri:

Titolo	Nome e localita dell' Istituzione	Data
Medico	Center for Comprehensive Health Practice, New York, NY, USA	1992-97
Medico (Ospedaliero) Assistente	NewYork-Presbyterian Hospital, New York, NY, USA	2008-22
Medico (Ospedaliero) Associato	NewYork-Presbyterian Hospital, New York, NY, USA	2022-24
Medico Consulente	Hospital for Special Surgery, New York, NY, USA	2008-24

E. LICENZE, ABILITAZIONI SPECIALISTICHE

Licenze:

Stato	Numero	Data (m/g/a)
Iscrizione all'ordine dei medici della provincia di Lecce, Italia	4426	31/12/86
Licenza medica dello Stato di New York, USA	233172	06/30/04-
Numero DEA (autorizzazione della agenzia federale antidroga)	BS9693260 BX9693269 (permesso per buprenorfina)	
Numero NPI (Numero di identificazione nazionale)	1043364631	

Abilitazioni:

Nome dell Organismo Abilitante	Data
Abilitazione alla professione medica e chirurgica	1986
Organismo Americano di Abilitazione in Medicina Interna	2006-
Organismo Americano di Abilitazione in Malattie Infettive	2007-

F. PREMI E ONORIFICENZE

Nome del premio/ onorificenza	Organizzazione	Data
M.D., <i>Summa Cum Laude</i>	Universita Cattolica Del Sacro Cuore, Roma, Italia	1986

Premio di Medicina di Prevenzione delle Popolazioni	Ministero Della Sanita', Roma, Italia	1987
Premio Lilly-Humulin	Universita' Cattolica Del Sacro Cuore, Roma, It	1989
Borsa di studio finalizzata alla lotta all'AIDS	Istituto Superiore di Sanita', Roma, Italia	1999
Young Investigator award	Stony Wold – Herbert Fund	2006
Premio per l'articolo piu citato negli anni 2006-2008	Journal of Hepatology	2009
Affinito-Steward Leadership Award	President's Council of Cornell Women (PCCW)	2014
Nomina a Fellow	Infectious Disease Society of America	2018
Spokeperson	Infectious Disease Society of America	2020-
Presidente del comitato direttivo per la ricerca dello studio PRESCO	Brin Foundation/Verily	2021
Elezione a Councilor	Infectious Diseases Society of New York	2021-2023
ID Week Visiting Professor	Infectious Disease Society of America	2021
Certificato di riconoscenza per i contributi straordinari e servizio prestato nella Research Committee	Infectious Disease Society of America	2023
Membro su invito	Societa di Ricerca Scientifica Onoraria Sigma Xi	2024
Vice Presidente (percorso per Presidente in 2025)	Infectious Diseases Society of New York	2024-
Selezionata per il 2025 Community of Leaders programs	Infectious Disease Leadership Institute, Infectious Disease Society of America	2025

I. MEMBERSHIP AD ORGANIZZAZIONI E SOCIETÀ PROFESSIONALI

Organizatione	Data
Iscrizione all'ordine dei Medici, provincial di Lecce	1986-
Societa' Americana di Virologia (ASV)	1998-2012
Societa' Americana di Malattie Infettive (IDSA)	2006-
Infectious Disease Society of New York (IDSNY)	2006-
Societa' Americana di Microbiologia (ASM)	2011-
Societa' Internazionale di Medicina dei Viaggi (ISTM)	2011-2019
Societa' Internazionale per Influenza e Altri Virus Respiratori (ISIRV)	2016-

J. CONTRIBUTI EDUCATIVI

Insegnamento Didattico:

Docenze:	Data
Per gli studenti di Medicina	
Docente per gli studenti di medicina del secondo anno: Health, Illness, and Disease II Infectious Diseases: "Respiratory viral infections" (annuale)	2015-
Docente per gli studenti di medicina del secondo anno: Health, Illness, and Disease II Infectious Diseases: Covid-19 physician panel "Covid-19 immune responses"	2020
Per gli Specializzandi	
Docente per gli specializzandi di Malattie Infettive: Pre-travel consultation	2011
Docente per gli specializzandi di Malattie Infettive NYP-Queens (annuale)	2020-

Per lo staff clinico (Infermiere, medici, assistenti medici in training, assistenti sociali) dell'Istituto per il trattamento e ricerca delle dipendenze da oppioidi VP Dole	
In-service training lecture: "Hepatitis C diagnosis and treatment", annuale	2008-
In-service training lecture: "Covid Vaccines"	2020

Tutor:

Studenti di Medicina

Dates

Health, Illness, and Disease II (Everyday Infectious Disease): Sessioni per piccoli gruppi su malattie infettive e microbiologia clinica per gli student di medicina al secondo anno, 6 sessioni /anno	2008-
Medicine, Patients and Society II: Tutor Esame fisico, discussione della diagnosi differenziale dei reperti clinici	2008-10

Insegnamento Clinico

Dates

Preceptore clinico per studenti Physician Assistant	2009-20
Supervisore clinico e insegnante di medicina dei viaggi. Supervisore clinico delle Nurse practitioners nella clinica di medicina dei viaggi.	2009-13
Preceptore clinico per gli specializzandi che ruotano nella clinica di medicina del viaggio	2009-13
Insegnante responsabile del servizio di consulenza in malattie infettive in reparto di degenza da parte degli specializzandi	2009-
Insegnante responsabile della clinica ambulatoriale per gli specializzandi in medicina delle dipendenze	2021

Incarichi:

Dates

Direttore per la serie di seminari con crediti CME (di Educazione Continua): Community and Public Health Research Rounds (1 seminario al mese da Ottobre a Maggio) (Organizatione, selezione and introduzione dei relatori, amministrazione)	2010-14
--	---------

Community education or patient outreach

Our Voices, Strategica Communication (NYC): <i>Vaccino anti-covid tutto quello che c'e' da sapere (Educazione for Italiani in NYC sui vaccini per il COVID)</i>	30/11/2020
---	------------

L. ATTIVITA CLINICA E LEADERSHIP

Pratica Clinica	Data
Medico, Center for Comprehensive Health Practice, New York, NY	1992-95
Medico, Vincent P. Dole Research and Treatment Institute for Opiate Dependency, New York Presbyterian hospital	2008-
Medico del Servizio di Consulenza di insegnamento in malattie infettive, New York Presbyterian hospital	2008-

Attività di Leadership Clinica/Amministrativa	Data
Direttore Medico della clinica di malattie infettive e medicina dei viaggi (Ha guidato la transizione della clinica da documentazione cartacea al Sistema computerizzato EPIC e ha implementato il Physician Quality Reporting System (PQRI). Ha partecipato alla selezione ed assunzione dello staff clinic e nelle Nurse practitioners. Ha guidato il training e supervision dello staff e delle nurse practitioners	2009-13

M. RICERCA

Attività' di Ricerca clinica:

Protocolli IRB attivi:

20-12023076	Salvatore, Mirella	Randomized double-blind, placebo-controlled pilot study of the efficacy and safety of baloxavir in combination with standard of care in stem cell transplant patients hospitalized for influenza 10/25/2022
20-03021645	Salvatore, Mirella	Viral characteristics and host responses to novel coronavirus SARS-2 infection and vaccination
19-11021069	Mason, Christopher	Rapid Diagnosis of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)
1506016280	Salvatore, Mirella	Epidemiological/ viral factors and influenza and other respiratory viral infection disease outcome 04/12/2022
1206012440	Crystal, Ronald	Phase I randomized, double-blind, placebo control study for an anti-cocaine vaccine 08/23/2022
1105011710	Soave, Rosemary	Infectious Complications of Immunosuppression
0910010689	Salvatore, Mirella	INSIGHT H1N1v Hospitalization Study (FLU 003): An International Observational Study to Characterize Hospitalized Adults with Influenza A - Pandemic H1N1 (H1N1v) 07/09/2022

Protocolli IRB terminati:

1804019176	Salvatore, Mirella	Harnessing the blood transcriptome to study the effects of multiple vaccinations in travelers 12/16/2020
20-08022553	Salvatore, Mirella	Predictors of Severe COVID-19 Outcomes (PRESCO) 09/21/2022
20-04021761	Evering, Teresa	Establishment and Characterization of a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Cohort in Humans to Understand Disease Pathogenesis 07/13/2021
1501015825	Salvatore, Mirella	Longitudinal characterization of the respiratory microbiome diversity and host gene expression after influenza and other respiratory viral infections. 03/02/2018
1411015644	Salvatore, Mirella	Longitudinal characterization of the respiratory microbiome diversity and host gene expression during hematopoietic stem cell transplant (HSCT) and respiratory infections. 01/16/2018
1410015615	Small, Catherine	GS-US-218-1502: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS-5806 in Hematopoietic Cell Transplant (HCT) Recipients with Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract 12/18/2017
1410015586	Small, Catherine	GS-US-218-0108: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS-5806 in Hematopoietic Cell Transplant (HCT) Recipients with Respiratory Syncytial Virus (RSV) Infection of the Upper Respiratory Tract. 12/18/2017

1408015409 Small, Catherine	GS-US-218-1227 - A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS-5806 in Hospitalized Adults with Respiratory Syncytial Virus (RSV) Infection 10/09/2017
1403014933 Soave, Rosemary	DAS181-2-05: A Phase II, Randomized, Double-blind, Placebo controlled study to examine the effects of DAS181 in immunocompromised subjects with Lower Respiratory Tract Parainfluenza Infection on Supplemental Oxygen 10/24/2017
0910010688 Glesby, Marshall	INSIGHT Outpatient Study (FLU 002 Plus): An International Observational Study to Characterize Adults with Influenza or Other Targeted Respiratory Viruses 05/22/2017
0306006211	Beeder, Ann Community Health and Health Care Study. 04/27/2017

Protocolli IACUUC (studi su animali)

2009-045 Integrase-defective lentiviral based influenza vaccines (2009-2019)

GRANT:

Fondi di Ricerca Attuali

Fonte (del finanziamento):	National Institute of Allergy and Infectious Diseases (NIAID) 1R21AI182901-01
Titolo del progetto:	The effects of immunosuppression on SARS-CoV-2 persistence, virus genetic diversity and clinical outcomes of COVID-19
Durata del supporto:	July 7, 2024-June 30, 2025
Ruolo nel Progetto	PI
Gli scopi principali del progetto sono:	Valutare l'effetto dello stato immunitario dell'ospite e della terapia sulla diversità virale e sull'esito della malattia

Grant Sottomessi:

Fonte (del finanziamento):	National Institutes of Health 1R01 RHL180875A
Titolo del progetto:	A Systems Approach Towards Opioid Use Disorder, Neuro-Immune Interactions, and Vaccinations in Adults with HIV
Durata del supporto:	July 1, 2025-June 30, 2030
Ruolo nel Progetto	PI (Evering Co-Pi)
Gli scopi principali del progetto sono:	Valutare la relazione tra vaccinazione, uso di oppioidi e neuroinfiammazione nelle persone con HIV
Fonte (del finanziamento):	National Institutes of Health 1 R01 DA064066-01
Titolo del progetto:	Fungal Drivers of Lung Inflammation
Durata del supporto:	July 1, 2025-June 30, 2030
Ruolo nel Progetto	Co-investigator (Iliyan D Iliev PI)
Fonte (del finanziamento):	CEIRS/NIH
Titolo del progetto:	<i>Immunosuppression as driver of influenza diversity, persistence, and outcome</i>

Durata del supporto:	June 1, 2025-July 30, 2027
Ruolo nel Progetto	PI
Gli scopi principali del progetto sono:	Integrare i dati clinici dei pazienti, il profilo immunitario e il sequenziamento del virus per determinare l'effetto dell'immunità dell'ospite e dei trattamenti ricevuti sulla evoluzione del virus dell'influenza all'interno dell'ospite e l'effetto di questa evoluzione sull'esito della malattia.

Grant Completati:

Fonte (del finanziamento):	National Institute of Allergy and Infectious Diseases (NIAID): NIH 5T32AI007623-09
Titolo del progetto:	Pathogenesis of Infectious Diseases Training Program
Durata del supporto:	July 2003 - June 2004
Ruolo nel Progetto	Trainee (M. Klotman PI)

Fonte (del finanziamento):	Stony Wold – Herbert Fund Young investigator
Titolo del progetto:	Inhibition of Influenza Virus Replication by Alpha-defensin
Durata del supporto:	July 2006-June 2009
Ruolo nel Progetto	PI

Fonte (del finanziamento):	National Institute of Allergy and Infectious Diseases Award ID: HHSN272200900001/2/3I Task Order N.1
Titolo del progetto:	Influenza Combination Antiviral Focus Group
Durata del supporto:	11/2009-11/2010
Ruolo nel Progetto	PI, Subaward

Fonte (del finanziamento):	National Institute of Allergy and Infectious Diseases (NIAID): Award ID: 5 R21 AI073926
Titolo del progetto:	Integrase-defective Lentiviral Based Influenza Vaccines
Durata del supporto:	July 2009 - September 2012
Ruolo nel Progetto	PI

Fonte (del finanziamento):	Weill Cornell CTSC Pilot award
Titolo del progetto:	Immune Responses to Influenza Vaccination in Opioid Users
Durata del supporto:	July 2010- June 2012
Ruolo nel Progetto	PI

Fonte (del finanziamento):	Feldstein Medical Foundation
Titolo del progetto:	Targeted Vector Delivery for Rapid Protection from Infectious Disease
Durata del supporto:	July 2012-June 2013
Ruolo nel Progetto	PI

Fonte (del finanziamento):	National Institute on Drug Abuse (NIDA) 5R01DA029512
Titolo del progetto:	Subcontracted by: SUNY Downstate Medical Center Integrated vs. Separate Care for Hepatitis C, Substance Abuse, and HIV Prevention
Durata del supporto:	4/2010-1/2017
Ruolo nel Progetto	Co-investigator (A. Beeder PI)

Fonte (del finanziamento):	Einaudi Foundation
Titolo del progetto:	Development of a Research Network with Singapore for the study of Chikungunya and other emerging viral infections
Durata del supporto:	7/2014-6/2016
Ruolo nel Progetto	PI
Fonte (del finanziamento):	PCCW Affinito-Stewart Grant
Titolo del progetto:	Integrase-Defective Lentiviral-Based Influenza Vaccine expressing NP. Role of NP-specific antibody and CD4+/CD8+ T cell subsets in protection
Durata del supporto:	7/2014-6/2016
Ruolo nel Progetto	PI
Fonte (del finanziamento):	The Gladys and Roland Harriman Foundation
Titolo del progetto:	Integrase Defective Lentiviral Vectors for Antibody Delivery against Influenza
Durata del supporto:	May 2016-April 2017
Ruolo nel Progetto	PI
Fonte (del finanziamento):	Ansun BioPharma, Inc.
Titolo del progetto:	Clinical trial: DAS181-2-05: A Phase II, Randomized, Double-blind, Placebo controlled study to examine the effects of DAS181 in immunocompromised subjects with Lower Respiratory Tract Parainfluenza Infection on Supplemental Oxygen
Durata del supporto:	2015- 2017
Ruolo nel Progetto	Co-investigator (R. Soave PI)
Fonte (del finanziamento):	Gilead Sciences, Inc.
Titolo del progetto:	Clinical trial: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS-5806 in Hematopoietic Cell Transplant (HCT) Recipients with Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract
Durata del supporto:	2015- 2017
Ruolo nel Progetto	Co-investigator (R. Soave PI)
Fonte (del finanziamento):	National Institute on Drug Abuse (NIDA)
Titolo del progetto:	1 U01 DA033835 Disrupted Adenovirus Serotype 5-based Anti-cocaine Vaccine
Durata del supporto:	8/2012-5/2018
Ruolo nel Progetto	Co-investigator (R. Crystal PI)
Fonte (del finanziamento):	National Institute of Allergy and Infectious Diseases
Titolo del progetto:	Integrase Defective Lentiviral Vectors for Antibody Delivery against Influenza 1R21 AI124141
Durata del supporto:	July 2016- June 2019
Ruolo nel Progetto	PI

Fonte (del finanziamento):	Glaxo SmithKline
Titolo del progetto:	207266 / A Study to Evaluate the Viral RNA Copy Number of Influenza A and B Viruses in Symptomatic Adults by Use of Three Different Specimen Collection Techniques
Durata del supporto:	2017
Ruolo nel Progetto	Site PI
Fonte (del finanziamento):	International Society of Travel Medicine
Titolo del progetto:	Harnessing the Blood Transcriptome to Study the Effects of Multiple Vaccinations in Travelers
Durata del supporto:	2018- 2021
Ruolo nel Progetto	PI
Gli scopi principali del progetto sono:	Studiare l'effetto della somministrazione combinata di vaccini rispetto al vaccino singolo a livello di espressione proteica.
Fonte (del finanziamento):	National Institute on Drug Abuse (NIDA)
Titolo del progetto:	1 U01 DA048524 Clinical Assessment of Anti-cocaine Vaccine dAdGNE in Cocaine Addicts
Durata del supporto:	2019-2022
Ruolo nel Progetto	Co-investigator (R. Crystal PI)
Gli scopi principali del progetto sono:	<i>Testing a novel viral vector platform-based vaccine for cocaine addiction in human. Dose-escalation study</i>
Fonte (del finanziamento):	Genentech (investigator-initiated study)
Titolo del progetto:	Randomized Double-blind, Placebo-controlled Pilot Study of the Efficacy and Safety of Baloxavir in Combination with Standard of Care in Stem Cell Transplant Patients Hospitalized for Influenza NCT05170009
Durata del supporto::	July 1, 2022-June 30, 2024
Ruolo nel Progetto	PI
Gli scopi principali del progetto sono:	Valutare gli effetti sulla carica virale, l'emergere di varianti virali e l'efficacia clinica di una nuova terapia combinata per l'influenza nei pazienti sottoposti a trapianto di cellule staminali ospedalizzati per influenza
Fonte (del finanziamento):	National Institute of Health
Titolo del progetto:	Respiratory Virus Hospitalization Study (INSIGHT study FLU 003 Plus NCT01056185
Duration of support:	September 1, 2022 - August 30, 2024
Ruolo nel Progetto	Site PI
Gli scopi principali del progetto sono:	<i>Longitudinal Multicenter samples collection from patients with influenza of different severity</i>
Fonte (del finanziamento):	Sergey Brin Family Foundation / Verily
Titolo del progetto:	Predictors of Severe COVID-19 Outcomes (PRESCO)
Duration of support:	December 1, 2020 - March 30, 2022
Ruolo nel Progetto	Site PI
Gli scopi principali del progetto sono:	Raccolta di campioni longitudinale e multicentrica da pazienti con Covid-19 di diversa gravità per lo sviluppo di

biomarcatori predittivi della gravità e delle complicazioni a lungo termine del Covid-19 (PASC).

N. SUPERVISIONE

<i>Nome</i>	Rosella Petraroli
<i>Posizione</i>	PhD student, Istituto Superiore di Sanita' Rome
<i>Periodo di Supervisione</i>	1992-95
<i>Progetto/risultato</i>	Ha pubblicato numerosi manoscritti sulle mutazioni e presiposizione genetica alle malattie dei prioni
<i>Posizione attuale</i>	EMEA Market Development Leader - Clinical Next Generation Sequencing Division at Thermo Fisher Scientific
<i>Tipo of Supervisione</i>	Ricerca
<i>Nome</i>	Skanda Kadirgamar
<i>Posizione</i>	Columbia Preparatory School Student
<i>Periodo di Supervisione</i>	2005-06
<i>Progetto/risultato</i>	Ha imparato tecniche di laboratorio e culture cellulari
<i>Posizione e attuale</i>	UNKN
<i>Tipo of Supervisione</i>	Ricerca
<i>Nome</i>	Zuleika Michelini PhD
<i>Posizione</i>	Visiting summer student, Mount Sinai School of Medicine
<i>Periodo di Supervisione</i>	Summer 2007
<i>Progetto/risultato</i>	Coauthor to ref#28
<i>Posizione attuale</i>	Senior researcher, Istituto Superiore di Sanita'
<i>Tipo of Supervisione</i>	Ricerca
<i>Nome</i>	Arnaud Drouin, MD
<i>Posizione</i>	postdoctoral fellow
<i>Periodo di Supervisione</i>	8/2009-6/10
<i>Progetto/risultato</i>	Accepted into Pathology Residency
<i>Posizione attuale</i>	Adjunct Assistant professor, Tulane University
<i>Tipo of Supervisione</i>	Ricerca
<i>Nome</i>	Dahlene Fusco, MD,
<i>Posizione</i>	ID fellow (co-mentor)
<i>Periodo di Supervisione</i>	7/2009-6/10
<i>Progetto/risultato</i>	Ricerca pubblicata in <i>Vaccine</i> (ref #25)
<i>Posizione attuale</i>	Assistant Professor, Tulane University
<i>Tipo of Supervisione</i>	Influenza/ Ricerca
<i>Nome</i>	Ekatherina Moroz, MD
<i>Posizione</i>	postdoctoral fellow
<i>Periodo di Supervisione</i>	2010-12
<i>Progetto/risultato</i>	Obtained the CTSC certificate in Clinic Investigation and her work was published in <i>Vaccine</i> (ref #30)
<i>Posizione attuale</i>	Senior Application Scientist
<i>Tipo of Supervisione</i>	Protein Fluidics, Inc. · Full-time
	Ricerca
<i>Nome</i>	Judith Fontana, PhD

<i>Posizione</i>	postdoctoral fellow
<i>Periodo di Supervisione</i>	2010-14
<i>Progetto/risultato</i>	Ha presentato a numerose conferenze nazionali, come il meeting della American Society for Virology dove ha vinto il Travel Grant. Ha ottenuto una borsa di studio dalla Stony Wold-Herbert Fund, rinnovata due volte. Ha pubblicato i lavori nelle Ref #27, 28, 38 e un capitolo di libro sull'Influenza.
<i>Posizione attuale</i>	Research Scientist at New York University
<i>Tipo of Supervisione</i>	Ricerca
<i>Nome</i>	Zuleika Michelini PhD
<i>Posizione</i>	Visiting postdoctoral fellow
<i>Periodo di Supervisione</i>	2016
<i>Progetto/risultato</i>	Ha presentato un abstract al meeting Options X for the Control of influenza, ha pubblicato un lavoro di ricerca su <i>Viruses</i>
<i>Posizione attuale</i>	Senior researcher, Istituto Superiore di Sanita'
<i>Tipo of Supervisione</i>	Ricerca
<i>Nome</i>	JianJun Yang, MS
<i>Posizione</i>	Technician 2
<i>Periodo di Supervisione</i>	2016-2019
<i>Progetto/risultato</i>	Co-author in #38, Submitted #2, in preparation #1)
<i>Posizione attuale</i>	Technician 2
<i>Tipo of Supervisione</i>	Ricerca
<i>Nome</i>	Khin Pyai, MD
<i>Posizione</i>	Research Associate
<i>Periodo di Supervisione</i>	Spring 2017-June 2020
<i>Progetto/risultato</i>	Ha presentato un abstract alla IDWeek 2018, vinto premio per presentazione del poster tra i Burmese trainees. E stata accettata nella scuola di specializzazione in Internal Medicine
<i>Posizione attuale</i>	Internal Medicine Resident
<i>Tipo of Supervisione</i>	Clinica/ Ricerca
<i>Nome</i>	Emily Coskun, MD
<i>Posizione</i>	Specializzando in Medicina Interna
<i>Periodo di Supervisione</i>	2019-2021
<i>Progetto/risultato</i>	Ha presentato un abstract all' Internal Medicine Research Retreat, e al meeting nazionale della American society of haematology
<i>Posizione attuale</i>	Attending, WCM
<i>Tipo of Supervisione</i>	Ricerca
<i>Nome</i>	Brian Chernak, MD
<i>Posizione</i>	Specializzando in Medicina Interna
<i>Periodo di Supervisione</i>	2019-2021
<i>Progetto/risultato</i>	Ha presentato un abstract all' Internal Medicine Research Retreat, e al meeting nazionale della American society of haematology. Ha vinto un Abstract Achievement Award al meeting nazionale della American society of haematology
<i>Posizione attuale</i>	Attending, Leukemia MSKCC

Tipo of Supervisione

Ricerca

Altre attivita' di supervisione:

<i>Nome</i>	Samantha Jacobs, MD
<i>Posizione</i>	Specializzanda in Malattie Infettive
<i>Periodo di Supervisione</i>	May-June 2014
<i>Progetto/risultato</i>	Master Clinical and Translational Investigation
<i>Posizione attuale</i>	Assistant Professor, Mount Sinai
<i>Tipo of Supervisione</i>	Expert Evaluator, Examination Committee for CTSC Master Thesis
<i>Nome</i>	Arial Marciscano, MD
<i>Posizione</i>	Assistant Professor, Division of Radiation Oncology
<i>Periodo di Supervisione</i>	2020
<i>Progetto/risultato</i>	Ha presentato un abstract al meeting annual della American Society of Radiation Oncology
<i>Tipo of Supervisione</i>	Mentor per la sezione sull'influenza dell' NIH Spore grant
<i>Nome</i>	Shenghao Tan, PhD
<i>Posizione</i>	PhD, Cornell Ithaca bioengineering school
<i>Periodo di Supervisione</i>	Summer 2021
<i>Progetto/risultato</i>	NA
<i>Posizione attuale</i>	same
<i>Tipo of Supervisione</i>	Clinical/ Ricerca summer mentor in training program

O. ATTIVITA ISTITUTIONALI AMMINISTRATIVE

Nome del Comitato	Ruolo	Data
Substance Use Disorder/Opioid workgroup Funzione: Review le linee guida per la prescrizione degli opioid e definisce le risorse disponibili al New York Presbyterian Hospital/Weill Cornell Medicine per il trattamento delle dipendenze da opioidi	Membro	2017-18
General Faculty Council , Weill Cornell Medicine Rappresentante per gli accademici a tempo pieno del Departmento of Medicina – Divisioni di Malattie Infettive, Allergia, Reumatologia, Epidemiologia Clinica, Salute Pubblica, Geriatria	Membro	2019-22
Research, Clinical Affairs and Benefits Subcommittee of the General Faculty Council	Membro	2019-

K. RESPONSABILITA' PROFESSIONALI ESTERNE

Partecipazione a commissioni o comitati

Nome del Comitato	Ruolo	Organizzazione /Istituzione Località	Data
Regionali (Stato di New York)			

PhD thesis defense, Jennifer Couret	Membro esterno di Commissione	Public Health Research Institute, University of Medicine and Dentistry of New Jersey	2017
PhD thesis proposal Katherine Evelyn Elizabeth Johnson	Membro esterno di Commissione	New York University	2018-2023
Infectious Diseases Society of New York (IDSNY)	Councilor	Infectious Diseases Society of New York, New York	2021-2023
Infectious Diseases Society of New York (IDSNY)	Vice presidente (a seguire Presidente Eletto, Presidente, Presidente Passato)	Infectious Diseases Society of New York, New York	2024-2027

Nazionali (USA)			
Influenza Research Collaboration (IRC)-Combination Antiviral Focus Group	Membro	National Institutes of Health - National Institute of Allergy and Infectious Diseases (NIH-NIAID)	2009-2010
Research Committee	Membro	Infectious Diseases Society of America (IDSA)	2019-2023
Continuing Education Subcommittee	Membro	Infectious Diseases Society of America (IDSA)	2024-

Internazionali

Research and Awards Committee	Membro	International Society of Travel Medicine	2017-2021
-------------------------------	--------	--	-----------

Revisione di Grant/Sezioni di Studio

Ruolo	Nome dell'organizzazione	Data
Revisore di grant	Swiss National Science Foundation	6/2010
Revisore di grant	NIH/NAID Scientific Review Panel, NIH Loan Repayment Program	6/2014
Revisore di Abstracts	Translational Science Meeting, Washington DC	6/2015
Revisore di "Pandemic Influenza Scenario"	World Health Organization (WHO)	12/2016
Revisore di grant	Swiss National Science Foundation	7/2017
Revisore di grant	International Society of Travel Medicine	2018-21

Revisore di Abstracts	Simposio di ricerca Du Vigneaud per ricerca condotta dai Graduate Students, Weill Cornell Medicine	2016-20
Revisore di grant	NIH/NAID Scientific Review Panel, Special emphasis panel RFA AI-17-037 Immunity in the elderly	7/2018
Revisore di Abstracts	ID Week 2020 (Infectious Disease Society of America Annual Meeting)	6/2020
Revisore di grant	NIH/NAID Scientific Review Panel ZAI1 JHM-X (S3) Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)	6/2020
Revisore di grant	NIH/NAID Scientific Review Panel ZAI1 LRW (J2) Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)	11/2020
Revisore di Abstracts	ID Week 2021, (Infectious Disease Society of America Annual Meeting)	6/2021
Revisore di grant	NIEHS P30 Pilot Grant Application	2/2023
Revisore di grant	Swiss National Science Foundation Bridge – Discovery grant	7/2023
Revisore di grant	NIH/NAID Scientific Review Special emphasis panel ZAI1 VSR-I (S1)1 RFA 22-060 Immunity in older adults	8/2023
Revisore di grant	Emerging Clinician Scientist Awards , Health Research Board (HRB), Ireland.	4/2024
Revisore di grant	NIH/NAID Scientific Review Special Emphasis Panel (ZAI1-RD-D-S2) PA24-141 R13 NIH Support for Conferences and Scientific Meetings	6/2024
Revisore di grant	NIH/NAID Scientific Review Special Emphasis Panel ZAI1-SAG-M-M1-U01	2/2025

Attività Editoriali

Membro di Board Editoriali

- Editorial Board and Associate Editor: *Frontiers in Medicine* 2019-
- Editorial Board and Associate Editor: *Frontiers in Public Health*, section of Infectious Diseases – Surveillance, Prevention and Treatment
- Editorial Associate Editor: *Vaccine* 2019-

Revisore di Pubblicazioni/Riviste

- *Annals of Internal Medicine*
- *Annals of Hematology*
- *Expert Opinion on Biological Therapy*
- *Frontiers in Immunology*
- *Journal of Virology*
- *Influenza and Other Respiratory Viruses*
- *International Journal of Molecular sciences*
- *International Journal of Environmental Research and Public Health*
- *Microbiome*
- *Nutrients*
- *Open Forum Infectious Diseases*
- *PlosOne*
- *The ISME Journal*
- *Seminars in Immunology*
- *Scientific Reports*
- *Translational Research*
- *Tropical Medicine and Infectious Disease*
- *Vaccine*
- *Vaccines*
- *Virology Journal*
- *Virus Research*
- *Viruses*

L. PRESENTAZIONI AD INVITO

Regionali (Stato di New York)

<u>Titolo</u>	<u>Istituzione/Località</u>	<u>Data (m/g/a)</u>
Novel therapies for influenza	Memorial Sloan Kettering Cancer Center, New York, NY	2010
Mucosal immunity and immunization	Hot Topics in Infectious Diseases, NYU Biology Graduate School, New York	5/23/2016
Fighting the Flu: Advances in Influenza Treatment	Practicing Clinicians Exchange (PCE) Symposia Series CME educational series for medical professional organized by the Boston University), Newark, NJ	6/23/2018
Influenza 2019: Emerging Vaccination and Therapeutic Strategies	Advanced Topics in Infectious Diseases, Memorial Sloan Kettering Cancer Center: New York, NY	3/15/2019
		9/6/2019

Integrase- defective lentiviral based approach to influenza vaccine	Department of Microbiology, Biochemistry & Molecular Genetics, Public Health Research Institute, UMDNJ, Newark, NJ	
Influenza prevention and treatment: current approaches and emerging concepts”	Medical Grand Rounds NYPH Queens, New York, NY	10/16/2019
Harnessing human Covid-19 Cohorts and immune-omics integration for disease predictions	Cornell, Ithaca & Weill Cornell Medicine COVID-19 Summit	11/5/2020
Vaccines for prevention of influenza and COVID-19	NYPH Queens Infectious Disease Seminar Series, New York, NY	12/30/2020
Overcoming Challenges in the treatment of Influenza	Flushing Hospital Medical Center, Department of Medicine Grand Rounds:	2/9/2020
Flu Season 2021: What to Expect & How to Prepare	New York Presbyterian Fall 2021 Health and Wellness Seminar Series	10/5/2021
Metabolic and immune markers for precise monitoring of COVID-19 severity and treatment	University of Rochester Medical Center, Allergy, Immunology and Rheumatology Grand Rounds	11/11/2021
Covid-19: Immunological and metabolic findings	NYP Queens Infectious Disease Seminar Series	11/19/2021
COVID-19: Treatment Options and Therapeutic Challenges	New York-Presbyterian Queens Infectious Disease Lecture Series	11/18/2022
Update on 2022 - 2023 seasonal Influenza	WCMA primary Care division, Weill Cornell Medicine	12/7/2022
Persistent SARS-CoV2 infection of the immunocompromised host. From bedside to bench and back	Department of Medicine, Icahn School of Medicine at Mount Sinai, NY, NY	9/10/2024
Emergence of resistance to COVID-19 treatments in the immunocompromised host. From bedside to bench and back	Infectious Disease Grand Round Robert Wood Johnson Medical School New Brunswick, NJ	10/29/2024
Persistent COVID-19 infection in the immunocompromised host From bedside to bench and back	Infectious Disease Grand Round New York University New York,	12/13/2024

Nationali (USA)

<u>Titolo</u>	<u>Istituzione/Località</u>	<u>Data (m/g/a)</u>
Fighting the Flu: Advances in Influenza Treatment	Practicing Clinicians Exchange (PCE) 2018 Symposia Series (CME educational series for medical professional organized by the Boston University), Denver, CO	6/2/2018

Fighting the Flu: Advances in Influenza Treatment	Practicing Clinicians Exchange 2018 Symposia Series, CME educational series for medical professional organized by the Boston University), held in Cambridge, MA	11/3/2018
Overcoming challenges in the treatment of Influenza	Peerview Institute for Medical Education, CME live seminar series	11/12/2020
Responding to COVID-19 Variants	Consultant 360 Webinar series, COVID-19 Research Briefs	3/15/2021
Integrated omics analysis of host responses and COVID-19 severity	System Genomic Section, National Institute of Allergy and Infectious Disease (NIAID)	11/16/21
Novel therapies for COVID-19 and influenza	Johns Hopkins School of Medicine, Clinical Pharmacology Grand Rounds	4/27/2022
Flu Season 2022: What to Expect and How to Prepare.	Weill Cornell Medicine Wellness Series	12/8/2022
Emergence of resistance to COVID-19 treatments in the immunocompromised host	Infectious Disease Grand Round University of Maryland School of Medicine Baltimore, MA	11/10/2024

Internazionali

<u>Titolo</u>	<u>Istituzione/Località</u>	<u>Data (m/g/a)</u>
Updates on Influenza	Salzburg Seminar in Infectious Diseases, Salzburg, Austria	5/10/2019
Vaccines in the immunocompetent host	Salzburg Seminar in Infectious Diseases: Salzburg Austria	5/8/2019
Preventing a twindemic: Advances and challenges in flu and COVID-19 vaccine development	Weill Cornell Qatar Covid-19 Clinical webinar series	12/02/2020
Covid-19: the NYC experience and scientific advances	Federal University of Health Sciences of Porto Alegre, Global Health lecture series	11/9/2021
Precise monitoring of Covid-19 severity and treatment	8th European Scientific Working Group on Influenza (ESWI) Conference -Hot Topics on Influenza, RSV and Covid-19	12/5/21
One Health	Congresso Internazionale Corso 1980-1986 Università Cattolica del Sacro Cuore - Roma	9/20/2024
Emergence of resistance to COVID-19 treatments in the immunocompromised host	Options XII for the control of Influenza, Brisbane	10/1/2024

Interviste come Esperto:

AOL.com World's Worst Travel Diseases (And How To Avoid Them)	2011
Men's Health Magazine UK What to include in a vacation first aid kit	2013
Health Magazine What to include in a vacation first aid kit	2013

EverydayHealth.com Sanjay Gupta What travelers need to know about virus outbreaks https://www.everydayhealth.com/sanjay-gupta/what-travelers-need-to-know-about-virus-outbreaks.aspx	6/5/2013
Managed Health Care Dan Cook Educating Patients on Flu Vaccine Importance http://www.managedhealthcareconnect.com/content/educating-patients-flu-vaccine-importance	6/5/2017
Healio Infectious Disease News Vaccine refusal: What are the best ways to overcome it? http://www.healio.com/internal-medicine/infectious-diseases/news/print/infectious-disease-news/%7B34ed9aac-0831-41a0-8810-4efa8aff38c8%7D/vaccine-refusal-what-are-the-best-ways-to-overcome-it	5/2017
US News World Report Michael O. Schroeder Before You Travel: Have You Gotten Recommended Vaccines? <i>Take precautions if you're planning to go abroad.</i> http://health.usnews.com/health-care/patient-advice/articles/2017-07-04/before-you-travel-have-you-gotten-recommended-vaccines	7/4/2017
The New York Times Alexandra S. Levine New York Today: Messy Weather and Flu Facts https://www.nytimes.com/2018/01/17/nyregion/new-york-today-messy-weather-and-flu-facts.html?rref=collection%2Fcolumn%2Fny-today-daily-briefings&action=click&contentCollection=nyregion&region=stream&module=stream_unit&version=latest&contentPlacement=1&pgtype=collection&_r=1	1/17/2018
The Village Voice Mary Bakija As Flu Rages, Food Workers Resist Calling in Sick https://www.villagevoice.com/2018/02/15/as-flu-rages-food-workers-resist-calling-in-sick/	2/15/2018
The New York Times Alexandra S. Levine New York Today: Flu Season returns https://static.nytimes.com/email-content/UR_6667.html?nlid=28025736 also referenced by Fox News https://www.foxnews.com/health/should-i-get-the-flu-shot-what-to-know-about-the-2018-19-flu-season	10/16/2018
NBC health news Shamard Charles What is a cruise ship quarantine? St. Lucia liner detained after measles outbreak	5/1/2019

https://www.nbcnews.com/health/health-news/what-quarantine-st-lucia-cruise-ship-detained-after-measles-outbreak-n1000841 Also referenced by: The Salon https://www.salon.com/2019/05/02/there-is-a-scientology-cruise-ship-and-it-has-just-been-quarantined-due-to-measles/ St Lucia News online: https://www.stlucianewsonline.com/doctors-explain-medical-quarantine-after-saint-lucia-cruise-ship-detained-due-to-measles-outbreak/	
Our Voices, Strategica Communication (NYC): <i>Vaccino anti-covid tutto quello che c'e' da sapere (Education for Italian in NYC on COVID vaccines)</i>	30/11/2020
NYP Health Matters What to Know About the New Coronavirus Variants https://healthmatters.nyp.org/what-to-know-about-the-new-coronavirus-variants/	2/2021
Medscape: What we know and what we do not know about virus variants https://www.medscape.com/viewarticle/944508	1/21/2021
Health Karen Pallarito Can You Safely Hang Out with Unvaccinated Friends? Here's What Doctors Recommend https://www.health.com/condition/infectious-diseases/coronavirus/can-you-hang-out-with-unvaccinated-friends?fbclid=IwAR0A91qG6ibuvPGri2WUWB58gESS-TuUVp-XliUSHWR2qk-gFCC5s5yOOons	7/21/21

Radio

NY Public Radio Please Explain this flu season https://www.wnyc.org/story/please-explain-flu-season/	2/23/2018
--	-----------

Podcasts

Infectious Disease Society of America Media Briefing: Coronavirus Variants https://www.idsociety.org/multimedia/videos/idsa-media-briefing-coronavirus-variants/	1/21/2021
Infectious Disease Society of America COVID-19 Podcast: COVID-19: Emerging Variants and the race to Vaccinate https://www.idsociety.org/multimedia/podcasts/covid-19-emerging-variants-and-the-race-to-vaccinate/	2/6/2021
VuMedi (medical education website): Will Emerging Coronavirus Variants Affect Overall Mortality? What Can We Do to Stay Ahead of the Evolving Scenario of More Transmissible Variants? https://www.vumedi.com/video/will-emerging-coronavirus-variants-affect-overall-mortality-what-can-we-do-to-stay-ahead-of-evolving/	2/1/2021
Science Writers of New York (SWINY): COVID-19 Variants and Vaccines: A Virtual Conversation with Dr. Mirella Salvatore https://www.youtube.com/watch?v=Sy_OYPX0qlw	2/3/2021

G. BIBLIOGRAFIA

OrcID: orcid.org/0000-0002-8296-0376

H index: 41

Citation 4192 (google scholar)

a. Articoli di Ricerca Originali Peer-Reviewed:

1. Manna R, **Salvatore M**, Pantoli D, Vecchio FM, Greco AV, Carosella L, Schiavino D, Ghirlanda G. Malignant histiocytosis: report of three cases. *Br J Clin Pract.* 1988 Feb;42(2):82-6. PubMed PMID: 3179178.
2. Manna R, **Salvatore M**, Scuderi F, Papa G, Marietti G, Greco AV, Ghirlanda G, Gambassi G. Negative correlation between ICA persistence and beta cell restoration after IDDM diagnosis. *Diabetes Res.* 1988 Nov;9(3):101-3. PubMed PMID: 3072142.
3. Manna R, **Salvatore M**, Amato S, Ghirlanda G, Scuderi F, Greco AV. HLA antigens and islet cell antibodies are useful for the identification of type 1 diabetes high risk subjects. *Acta Med Romana.* 1988; 3:340-344.
4. Manna R, **Salvatore M**, Di Leo MA, Scuderi F, Greco AV, Ghirlanda G, Gambassi G. Relationship between urinary neopterin excretion and islet cell antibodies in type 1 (insulin-dependent) diabetes. *Diabetes Res.* 1991 May;17(1):33-6. PubMed PMID: 1816978.
5. Magalini S.C., Nanni G., Agnes S., Avolio A.W., **Salvatore M**, Manna R., Castagneto M. Neopterin, amyloid A, C-reactive protein, gamma-interferon, and interleukin-2 receptor in diagnosis of posttransplantation rejection. *Transplant Proc.* 1991; 23(4):2267-8.
6. Magalini SC, Nanni G, Agnes S, Avolio AW, **Salvatore M**, Manna R, Migliore A, Liang L, Micantonio L, Ponte E, Marietti G, Pantanella G, La Valle C, Greco AV, Ghirlanda G. Ridotta secrezione insulinica rivelata dall'IVGTT nei consanguinei di primo grado di pazienti affetti da diabete insulino dipendente. *Giornale Italiano di Diabetologia* 1990 1:9-13.
7. Pocchiari M, **Salvatore M**, Ladogana A, Ingrosso L, Xi YG, Cibati M, Masullo C. Experimental drug treatment of scrapie: a pathogenetic basis for rationale therapeutics. *Eur J Epidemiol.* 1991 Sep;7(5):556-61. PubMed PMID: 1761115.
8. Ladogana A, Casaccia P, Ingrosso L, Cibati M, **Salvatore M**, Xi YG, Masullo C, Pocchiari M. Sulphate polyanions prolong the incubation period of scrapie-infected hamsters. *J Gen Virol.* 1992 Mar;73 (Pt 3):661-5. PubMed PMID: 1372039.
9. Pocchiari M, Masullo C, **Salvatore M**, Genuardi M, Galgani S. Creutzfeldt-Jakob disease after non-commercial dura mater graft. *Lancet.* 1992 Sep 5;340(8819):614-5. PubMed PMID: 1355193.
10. Pocchiari M, **Salvatore M**, Cutruzzolá F, Genuardi M, Allocatelli CT, Masullo C, Macchi G, Alemá G, Galgani S, Xi YG. A new point mutation of the prion protein gene in Creutzfeldt-Jakob disease. *Ann Neurol.* 1993 Dec;34(6):802-7. PubMed PMID: 7902693.
11. Masullo C, **Salvatore M**, Macchi G, Genuardi M, Pocchiari M. Progressive dementia in a young patient with a homozygous deletion of the PrP gene. *Ann N Y Acad Sci.* 1994 Jun 6;724:358-60. PubMed PMID: 8030960.
12. **Salvatore M**, Genuardi M, Petraroli R, Masullo C, D'Alessandro M, Pocchiari M. Polymorphisms of the prion protein gene in Italian patients with Creutzfeldt-Jakob disease. *Hum Genet.* 1994 Oct;94(4):375-9. PubMed PMID: 7927332.
13. **Salvatore M**, Seeber AC, Nacmias B, Petraroli R, D'Alessandro M, Sorbi S, Pocchiari M. Apolipoprotein E in sporadic and familial Creutzfeldt-Jakob disease. *Neurosci Lett.* 1995 Oct 20;199(2):95-8. PubMed PMID: 8584252.
14. **Salvatore M**, Pocchiari M, Cardone F, Petraroli R, D'Alessandro M, Galvez S, Brown P, Macchi G, Fieschi C, Colosimo C. Codon 200 mutation in a new family of Chilean origin with Creutzfeldt-Jakob disease. *J Neurol Neurosurg Psychiatry.* 1996 Jul;61(1):111-2. PubMed PMID: 8676137;

15. Barbanti P, Fabbrini G, **Salvatore M**, Petraroli R, Cardone F, Maras B, Equestre M, Macchi G, Lenzi GL, Pocchiari M. Polymorphism at codon 129 or codon 219 of PRNP and clinical heterogeneity in a previously unreported family with Gerstmann-Sträussler-Scheinker disease (PrP-P102L mutation). *Neurology*. 1996 Sep;47(3):734-41. PubMed PMID: 8797472.
16. **Salvatore M**, Seeber AC, Nacmias B, Petraroli R, Sorbi S, Pocchiari M. Alpha1 antichymotrypsin signal peptide polymorphism in sporadic Creutzfeldt-Jakob disease. *Neurosci Lett*. 1997 May 16;227(2):140-2. PubMed PMID: 9180223.
17. **Salvatore M**, Morzunov S, Schwemmler M, Lipkin WI. Borna disease virus in brains of North American and European people with schizophrenia and bipolar disorder. Borna disease virus Study Group. *Lancet*. 1997 Jun 21;349(9068):1813-4. PubMed PMID: 9269221.
18. Schwemmler M*, **Salvatore M***, Shi L, Richt J, Lee CH, Lipkin WI. Interactions of the borna disease virus P, N, and X proteins and their functional implications. *J Biol Chem*. 1998 Apr 10;273(15):9007-12. PubMed PMID: 9535888. ***equal contribution**
19. Talon J, **Salvatore M**, O'Neill RE, Nakaya Y, Zheng H, Muster T, García-Sastre A, Palese P. Influenza A and B viruses expressing altered NS1 proteins: A vaccine approach. *Proc Natl Acad Sci U S A*. 2000 Apr 11;97(8):4309-14. PubMed PMID: 10725408.
20. Basler CF, Reid AH, Dybing JK, Janczewski TA, Fanning TG, Zheng H, **Salvatore M**, Perdue ML, Swayne DE, García-Sastre A, Palese P, Taubenberger JK. Sequence of the 1918 pandemic influenza virus nonstructural gene (NS) segment and characterization of recombinant viruses bearing the 1918 NS genes. *Proc Natl Acad Sci U S A*. 2001 Feb 27;98(5):2746-51. PubMed PMID: 11226311.
21. **Salvatore M**, Basler CF, Parisien JP, Horvath CM, Bourmakina S, Zheng H, Muster T, Palese P, García-Sastre A. Effects of influenza A virus NS1 protein on protein expression: the NS1 protein enhances translation and is not required for shutoff of host protein synthesis. *J Virol*. 2002 Feb;76(3):1206-12. PubMed PMID: 11773396.
22. Geiss GK*, **Salvatore M***, Tumpey TM, Carter VS, Wang X, Basler CF, Taubenberger JK, Bumgarner RE, Palese P, Katze MG, García-Sastre A. Cellular transcriptional profiling in influenza A virus-infected lung epithelial cells: the role of the nonstructural NS1 protein in the evasion of the host innate defense and its potential contribution to pandemic influenza. *Proc Natl Acad Sci U S A*. 2002 Aug 6;99(16):10736-41. PubMed PMID: 12149435. *** equal contribution**
23. Bräu N, **Salvatore M**, Ríos-Bedoya CF, Fernández-Carbia A, Paronetto F, Rodríguez-Orengo JF, Rodríguez-Torres M. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. *J Hepatol*. 2006 Jan;44(1):47-55. Epub 2005 Jul 27. PubMed PMID: 16182404.
24. **Salvatore M**, Garcia-Sastre A, Ruchala P, Lehrer RI, Chang T, Klotman ME. alpha-Defensin inhibits influenza virus replication by cell-mediated mechanism(s). *J Infect Dis*. 2007 Sep 15;196(6):835-43. Epub 2007 Aug 10. PubMed PMID: 17703413.
25. Fusco D, Liu X, Savage C, Taur Y, Xiao W, Kennelly E, Yuan J, Cassileth B, **Salvatore M**, Papanicolaou GA. Echinacea purpurea aerial extract alters course of influenza infection in mice. *Vaccine*. 2010 May 21;28(23):3956-62. Epub 2010 Apr 9. PubMed PMID: 20382242.
26. Negri DR, Bona R, Michelini Z, Leone P, Macchia I, Klotman ME, **Salvatore M**, Cara A. Transduction of human antigen-presenting cells with integrase-defective lentiviral vector enables functional expansion of primed antigen-specific CD8(+) T cells. *Hum Gene Ther*. 2010 Aug;21(8):1029-35. PubMed PMID: 20210625.
27. Fontana JM, Alexander E, **Salvatore M**. Translational research in infectious disease: current paradigms and challenges ahead. *Transl Res*. 2012 Jun;159(6):430-53. Epub 2012 Jan 15. Review. PubMed PMID: 22633095.
28. Fontana JM, Christos PJ, Michelini Z, Negri D, Cara A, **Salvatore M**. Mucosal immunization with integrase-defective lentiviral vectors protects against influenza virus challenge in mice. *PLoS One*. 2014;9(5):e97270. eCollection 2014. PubMed PMID: 24824623.

29. **Salvatore M**, Cara A. Anchoring IDLV: enhanced vectors for immunization. *Nucleic Acid Research*; 2014 2(7):e53.
30. Moroz E, Albrecht RA, Aden B, Beeder AB, Yuan J, García-Sastre A, Edlin BR, **Salvatore M**. Active opioid use does not attenuate the humoral responses to inactivated influenza vaccine. *Vaccine*. 2016 Mar 8;34(11):1363-9. Epub 2016 Feb 6. PubMed PMID: 26859239.
31. **Salvatore M***, Satlin MJ, Jacobs SE, Jenkins SG, Schuetz AN, Moss RB, Van Besien K, Shore T, Soave R. DAS181 for Treatment of Parainfluenza Virus Infections in Hematopoietic Stem Cell Transplant Recipients at a Single Center. *Biol Blood Marrow Transplant*. 2016 May;22(5):965-70. Epub 2016 Feb 22. PubMed PMID: 26904972. ***Corresponding author**
32. Zhou B, Deng YM, Barnes JR, Sessions OM, Chou TW, Wilson M, Stark TJ, Volk M, Spirason N, Halpin RA, Kamaraj US, Ding T, Stockwell TB, **Salvatore M**, Ghedin E, Barr IG, Wentworth DE. Multiplex Reverse Transcription-PCR for Simultaneous Surveillance of Influenza A and B Viruses. *J Clin Microbiol*. 2017 Dec;55(12):3492-3501. PubMed PMID: 28978683.
33. Gallinaro A, Borghi M, Bona R, Grasso F, Calzoletti L, Palladino L, Cecchetti S, Vescio MF, Macchia D, Morante V, Canitano A, Temperton N, Castrucci MR, **Salvatore M**, Michelini Z, Cara A, Negri D. Integrase Defective Lentiviral Vector as a Vaccine Platform for Delivering Influenza Antigens. *Front Immunol*. 2018;9:171. eCollection 2018. PubMed PMID: 29459873.
34. Ding T, Song T, Zhou B, Geber A, Ma Y, Zhang L, Volk M, Kapadia SN, Jenkins SG, **Salvatore M***, Ghedin E*. Microbial Composition of the Human Nasopharynx Varies According to Influenza Virus Type and Vaccination Status. *mBio*. 2019 Jul 2;10(4). PubMed PMID: 31266874. ***Co-corresponding author**
35. Kodiyanplakkal RPL, Laplante JM, Westblade LF, van Besien K, **Salvatore M**, St George K. Detection and Characterization of Influenza B Virus With Reduced Neuraminidase Susceptibility in a Stem Cell Transplant Recipient. *Open Forum Infect Dis*. 2019 Dec;6(12):ofz493. doi: 10.1093/ofid/ofz493. eCollection 2019 Dec. PubMed PMID: 32128335.
36. Maldarelli GA, Savage M, Mazur S, Oxford-Horrey C, **Salvatore M**, Marks KM. Remdesivir Treatment for Severe COVID-19 in Third-Trimester Pregnancy: Case Report and Management Discussion. *Open Forum Infect Dis*. 2020 Sep;7(9):ofaa345. PubMed PMID: 32934969.
37. **Salvatore M***, Laplante JM, Soave R, Orfali N, Plate M, van Besien K, St George K. Baloxavir for the treatment of Influenza in allogeneic hematopoietic stem cell transplant recipients previously treated with oseltamivir. *Transpl Infect Dis*. 2020 Aug;22(4):e13336. Epub 2020 Jun 10. PubMed PMID: 32449254. ***Corresponding author**
38. Michelini Z, Minkoff JM, Yang J, Negri D, Cara A, Hanson BJ, **Salvatore M**. Integrase-Defective Lentiviral Vectors for Delivery of Monoclonal Antibodies against Influenza. *Viruses*. 2020 Dec 17;12(12). PubMed PMID: 33348840.
39. Rendeiro AF, Casano J, Vorkas CK, Singh H, Morales A, DeSimone RA, Ellsworth GB, Soave R, Kapadia SN, Saito K, Brown CD, Hsu J, Kyriakides C, Chiu S, Cappelli LV, Cacciapuoti MT, Tam W, Galluzzi L, Simonson PD, Elemento O, **Salvatore M***, Inghirami G*. Profiling of immune dysfunction in COVID-19 patients allows early prediction of disease progression. *Life Sci Alliance*. 2021 Feb;4(2). Print 2021 Feb. PubMed PMID: 33361110. ***Co-senior, co-corresponding author**
40. Butler D, Mozsary C, [...], **Salvatore M**, Loda M, Westblade LF, Cushing M, Wu S, Levy S, Chiu C, Schwartz RE, Tattonetti N, Rennert H, Imielinski M, Mason CE. Shotgun transcriptome, spatial omics, and isothermal profiling of SARS-CoV-2 infection reveals unique host responses, viral diversification, and drug interactions. *Nat Commun*. 2021 Mar 12;12(1):1660. PubMed PMID: 33712587.
41. Mathad JS, Lee MH, Chalem A, Frey MK, Chapman-Davis E, Koppam RV, Dayal AK, Wald G, Pinheiro LC, Satlin MJ, Goyal P, Safford MM, **Salvatore M***, Holcomb K*. Sex differences in Covid-19 presentation and outcomes in New York City: A cohort study. *Open Forum Infect Dis*. 2021 Jul 9;8(8):ofab370. PMID: 34381847 ***Equal contribution**

42. Rathnasinghe R, **Salvatore M**, Zheng H, Jangra S, Kehrer T, Mena I, Schotsaert M, Muster T, Palese P, García-Sastre A. Interferon mediated prophylactic protection against respiratory viruses conferred by a prototype live attenuated influenza virus vaccine lacking non-structural protein 1. 2021 *Sci Rep* 11, 22164. PMID 34401874 <https://doi.org/10.1038/s41598-021-01780-8>
43. Rendeiro AF, Vorkas CK, Krumsiek J, Singh H, Shashi Kapatia S, Cappelli LV, Cacciapuoti MT, Inghirami G, Elemento E, **Salvatore M**. Metabolic and immune markers for precise monitoring of COVID-19 severity and treatment. *Front Immunol*, 12 January 2022 | <https://doi.org/10.3389/fimmu.2021.809937>
44. Park J, Foox J, Hether T, [...] **Salvatore M**, Loda M, Westblade LF, Cushing M, Rennert H, Kriegel AJ, Elemento O, Imielinski M, Borczuk AC, Meydan C, Schwartz RE, Mason CE. System-wide loss of tissue identity in COVID-19 patients. *Cell Reports Medicine*, 2022, 1;24, 100522
45. Mzava O, Pellán [...] **Salvatore M**, Satlin M, Suthanthiran M, Lee J, Mason CE, Dadhania D, De Vlaminc I. A metagenomic DNA sequencing assay that is robust against environmental DNA contamination. *Nat Commun* 2022, 13: 4197
46. Wang C, Honce R, **Salvatore M.**, D. Chow, D. Randazzo, Yang J, Twells NM, Mahal LK, Schultz-Cherry S and Ghedin E. Reduced inflammatory response and promoted multiciliated cell differentiation in mice protected by defective interfering influenza virus. *J Virol* 2023, 97: 6.
47. Chen C, Parthasarathy, S, Leung, J, Wu, M; Drake, K; Ridaura, V; Zisser, H; Conrad, W; Tapson, V; Moy, J; deFilippi, C; Rosas, I; Prabhakar, B; Basit, M; **Salvatore, M**, Krishnan, J; Kim, C. Distinct temporal trajectories and risk factors for Post-acute sequelae of SARS-CoV-2 infection. *Front Med* 2023 Oct 16;10:1227883 eCollection 2023.
48. Drake KA, Talantov D, Tong GJ, Lin JT, Verheijden S, Katz S, Leung JK, PRESCO Study Group. Multi-omic Profiling Reveals Early Immunological Indicators for Identifying COVID-19 Progressors. *Clin Immunol*. 2023 Nov;256:109808. doi: 10.1016/j.clim.2023.109808. Epub 2023 Oct 16.
49. Xu C, Wang A, Ebrahim L, Sullivan L, Tasker C, Pizutelli V, Couret J, Hernandez C, Kolli P, Deb PQ, Fritzky L, Subbian S, Gao N, Lo Y, **Salvatore M**, Rivera A, Lemenze A, Fitzgerald-Bocarsly P, Tyagi S, Lu W, Beaulieu A, Chang TL. Interferon ϵ restricts Zika virus infection in the female reproductive tract. *PNAS Nexus*. 2023 Oct 25;2(11):pgad350.
50. Kusakabe T, Lin WY, Cheong JG, Singh G, Ravishankar A, Yeung ST, Mesko M, DeCelie MB, Carriche G, Zhao Z, Rand S, Doron I, Putzel GG, Worgall S, Cushing M, Westblade L, Inghirami G, Parkhurst CN, Guo CJ, Schotsaert M, García-Sastre A, Josefowicz SZ, **Salvatore M**, Iliev ID. Fungal microbiota sustains lasting immune activation of neutrophils and their progenitors in severe COVID-19. *Nat Immunol*. 2023 Nov;24(11):1879-1889. Epub 2023 Oct 23.
51. Early immune factors associated with the development of post-acute sequelae of SARS-CoV-2 infection in hospitalized and non-hospitalized individuals JM Leung, MJ Wu, P Kheradpour, VK Ridaura, J Allen, C Parsy-Kowalska, VF Tapson, JN Moy, CR deFilippi, JA Krishnan, BS Prabhakar, **M Salvatore**, CC Kim *Frontiers in Immunology* 15, 1348041
52. Nooruzzaman M, Johnson KEE, Rani R, Finkelsztejn EJ, Caserta LC, Kodiyanplakkal RP, Wang W, Hsu J, Salpietro MT, Banakis S, Albert J, Westblade L, Zanettini C, Marchionni L, Soave R, Ghedin E, Diel DG, **Salvatore M**. Emergence of transmissible SARS-CoV-2 variants with decreased sensitivity to antivirals in immunocompromised patients with persistent infections. *Nat Commun* 15, 7999 (2024). <https://doi.org/10.1038/s41467-024-51924-3>

b. Reviews and Editorials

1. **Salvatore M**, Pocchiari M. Biocontaminazione da virus lenti non-convenzionali. Proceedings of the V National Congress of the Association for the Study and Control of the Ambiental Pollution. 1991; 165-186.
2. **Salvatore M**, Garcia-Sastre A. Virus versus host: modulation of the host a/b interferon pathway by the influenza A virus NS1 protein. *International Congress Series*. 2001; 1219:513-520.

c. **Capitoli di Libri**

1. Manna, R., **Salvatore, M.** Gammopatie monoclonali e policlonali. in: Manuale di immunologia clinica. Nuova Italia Scientifica ed.1990; 9:101-105.
2. **Salvatore, M.**, Manna, R. Le immunodeficienze. in: Manuale di immunologia clinica. Nuova Italia Scientifica ed. 1990; 10: 107-118
3. Ghirlanda G, Manna R, **Salvatore M**, Greco AV. Prediction of type 1 diabetes: the Rome family study. In: Immunotherapy of type 1 diabetes. Andreani D, Kolb H, Pozzilli P, editors. New York: John Wiley & Sons; 1989. p.177-184.
4. **Salvatore M**, Meyers B. Metronidazole. In: Principles and Practice of Infectious Diseases. 8th ed. Mandell G, Douglas J, Bennett J, editors. Philadelphia: Churchill Livingstone; 2009. Chapter 29.
5. Meyers B. **Salvatore M.** Tetracyclines and Chloramphenicol. In: Principles and Practice of Infectious Diseases. 7th ed. Mandell G, Douglas J, Bennett JR, editors. Philadelphia: Churchill Livingstone; 2009. Chapter 27.
6. Meyers, B., **Salvatore, M.** Aseptic Meningitis Syndrome. In D. Schlossberg (Ed.), Clinical Infectious Disease. 2008; 513-520. Cambridge: Cambridge University Press. doi:10.1017/CBO9780511722240.075
7. Fontana JF, Eiras D, **Salvatore M.** Human Influenza Virus Infections. In: Human Respiratory Viral Infections. Sing SK, editor. Boca Raton, FL: CRC press Group; 2014. p.404-436

d. **Manoscritti sotto revisione per pubblicazione**

1. Ali R, Sule G , Lu C, Carmona-Rivera C, Lucotti S, Wu Q , Campbell PL, Gurrea Rubio, Fox S, Brodie , Mattichak M, Tambralli A , Yalavarthi, Ikari Y, Zuo WY, Imberti L, Caruso A , Caccuri F, Quaresima V, Sottini A, Kuhns D , Fink D , Castagnoli R, Delmonte O, Kenney H, Zhang Y, Magliocco M, Su H , Notarangelo L, Zemans R, Mao-Draayer Y , Matei I, **Salvatore M**, Lyden D, Kanthi Y, Kaplan M, Knight J, Fox D. Identification of CD13 and Its Soluble Form as Potential Mediators for Neutrophil-Induced Hyperinflammation and Thrombosis in SARS-CoV-2 Infection. *Under revision*
2. Clement CC, Rossini S , Volpi C, Shetty M, Rusinova R, Aitziber B, Galluzzi, Giorgio Inghirami, **Salvatore M**, Caielli S Pascual V, Lu T, L, D'Alessandro A, Soni R, Mota I, Guerin D, Orabona C, Yano H, Nguyen AM , Kumar S, Santambrogio The biogenic amine 3HKA restrains inflammation via non-canonical AhR signaling *Under revision*

e. **Articoli in Preparazione**

3. Manohar J, Abedian S, Martini R, Kulm S, **Salvatore M**, Ho K, Christos P, Campion T, Imperato-McGinley J, Ibrahim S, Evering TH, Phillips E, Tamimi R, Bea V, D Balogun O, Sboner A, Elemento O, Davis MB. Social and Clinical Determinants of COVID-19 Outcomes: Modeling Real-World Data from a Pandemic Epicenter. medRxiv. 2021 Apr 7. doi: 10.1101/2021.04.06.21254728. PubMed PMID: 33851193.
1. Michelini Z, Minkoff JM, Yang J, Cara, A, **Salvatore, M.** Intranasal administration of multi-antigen IDLV protect from homologous and heterosubtypical influenza challenge in mice (presented as a poster at: Options X for the Control of Influenza Singapore August 2019)
2. Chernak, B, Coskun E, Cooley V, Pao K, Soave R, Van Basin K, Shore T, **Salvatore M.** Clinical Characteristics and risk factors for adverse outcome of influenza infections in hematopoietic stem cell transplants
3. Ding T, Song T, Zhou B, Geber A, Ma Y, Satlin M, Soave RM, Jenkins S, Ghedin E, **Salvatore M.** Longitudinal of the respiratory microbiome in hematopoietic stem transplant recipient with respiratory viral infections.

SUMMARY OF PROFESSIONAL TRAINING AND ACTIVITIES

I am a physician-scientist with a longstanding interest in emerging infectious diseases. My dual training in Italy and the US has profoundly influenced both my research and professional interactions across different settings.

I earned my **MD with honors** from the Catholic University of Rome, Italy, and completed a fellowship in Endocrinology. Fascinated by prions after learning of cases following growth hormone contamination, I joined Professor Maurizio Pocchiari's group at the Catholic University and later at the Istituto Superiore di Sanità to study these intriguing agents. In 1996, I moved to the US to further my research and completed a postdoctoral fellowship in Neurovirology at the University of California, Irvine, in the lab of Ian Lipkin ("The Virus Hunter"). There, I studied Borna Disease Virus, an animal virus implicated in psychiatric disorders in humans. In 1998, I relocated to New York to work on pandemic influenza in the laboratory of Adolfo Garcia-Sastre at Mount Sinai School of Medicine, where I also completed a Residency in Internal Medicine and Fellowship in Infectious Diseases.

My **medical training** at Mount Sinai exposed me to healthcare inequalities and highlighted the importance of cultural and personal beliefs in disease treatment. During these years I treated high-income patients and veterans, rotated through a city hospital serving poor uninsured immigrants from Asia, India, and South America, encountering diseases rarely seen in the US. I worked as a visiting doctor in HIV housing and shelters, and conducted research in needle-exchange programs. These experiences deepened my understanding of the importance of studying global health. My work in infectious disease and travel medicine also continuously remind me of the importance of 'one health' and how global warming and antibiotic misuse are changing disease distribution and incidence.

In 2009, I joined Weill Cornell Medicine as Assistant, and later Associate, Professor of Medicine and Population Health. I continued my research on host responses to influenza, respiratory viruses, and vaccines. During the COVID-19 pandemic, I established a patient cohort and focused on identifying host responses and markers for predicting disease outcomes. I am the principal investigator and a steering committee member for PRESCO (Predictors of Severe COVID-19 Outcomes), a multi-institutional consortium studying COVID-19 patient data and samples for predictive tools. Currently I am studying how influenza and SARS-CoV-2 persist in immunocompromised hosts with hematologic malignancies and how this influence the development of drug resistance in these populations. My work in these years has led to publications in high-impact journals, including *Nature Communications*, *Nature Immunology*, *Cell Reports Medicine*, *Life Science Alliance*, *Frontiers in Immunology*, and *OFID*.

Beyond research, I have provided clinical care in infectious diseases and at the Vincent P. Dole Clinic, an integrated center for opioid use disorder treatment. I have taught both residents and medical students and served as Course Director for the "Community and Public Health Research Round" seminar series at Weill Cornell Medicine (2010-2014).

Over the years, I have developed strong **managerial skills** in both laboratory and clinical research, as well as in hospital practice. I have secured both basic and translational research funding, which has enabled me to manage technical staff, postdocs, students, and collaborate with numerous research groups. I have also managed clinical research studies and participated in regulatory activities. In the clinical setting, I served as Medical Director of the Infectious Diseases and Travel Medicine Clinic at Weill Cornell Medicine and managed clinical staff and help with budget.

I have held leadership roles in professional societies, including being the incoming president of the Infectious Diseases Society of New York, and have participated in national and international initiatives. I was selected by the Infectious Diseases Society of America for a management training course for emerging leaders in infectious diseases. Additionally, I have served as a grant reviewer for the NIH and as an editor.

My extensive international experience makes me well-suited for the Director position at the **Centro Nazionale per la Salute Globale** of the Istituto Superiore di Sanità. I would be honored to contribute to the success of this important institution.

A. PERSONAL DATA

Name **Mirella Salvatore**
Telephone:
Home address:
Email address - Personal: mirella.salvatore@gmail.com

Date February 6, 2025
Signature 
Mirella Salvatore

B. EDUCATION

Degree	Institution name and location	Date awarded
BA, Science	Scientific Lyceum, Nardo', Italy	1980
MD, <i>summa cum laude</i>	Catholic University Medical School, Rome, Italy	1986
MD (US)	ECFMG USMLE Certificate 0-592-692-8	2001

C. POSTDOCTORAL TRAINING

Title	Institution name and location	Dates
Residency, Diabetology and metabolic diseases <i>70/70 cum laude</i>	Catholic University Medical School, Rome, Italy	1986-89
Residency, Endocrinology <i>70/70 cum laude</i>	Il University of Rome "Tor Vergata", Rome, Italy	1989-92
Postdoctoral Fellow, Neurovirology	University of California Irvine, Irvine, CA Laboratory of Ian Lipkin	1996-98
Postdoctoral Fellow, Virology	Mount Sinai School of Medicine, New York, NY Department of Microbiology Laboratory of Adolfo Garcia-Sastre	1998-01
Fellow, Infectious Disease	Mount Sinai School of Medicine, New York, NY	2001-04
Resident, Internal Medicine	Mount Sinai School of Medicine, New York, NY	2004-06
Certificate in Travel Health	International Society of Travel Medicine	2011
Certificate in Clinical and Translational Investigation	Weill Cornell Medicine, New York, NY	2024

D. PROFESSIONAL POSITIONS

Academic and Research appointments:

Title	Institution city and state	Dates
Clinical Research Associate	Institute Servier, Paris, France	1991-92
Researcher (term), Virology	Istituto Superiore di Sanita' Rome, Italy	1992-95
Research Associate of Medicine	Mount Sinai School of Medicine, New York, NY	2006-08

Adj Assistant Professor of Medicine	Mount Sinai School of Medicine, New York, NY	2008-16
Assistant Professor of Medicine	Weill Cornell Medicine, New York, NY	2008-22
Assistant Professor of Public Health	Weill Cornell Medicine, New York, NY	2008-15
Assistant Professor of Population Health Sciences	Weill Cornell Medicine, New York, NY	2015-22
Associate Professor of Medicine	Weill Cornell Medicine, New York, NY	2022-24
Associate Professor of Population Health Science	Weill Cornell Medicine, New York, NY	2022-24
Senior Clinical Research Advisor	Audax Medical Inc, MA, USA	2024-

Hospital and Clinical appointments:

Title	Institution name and location	Dates
Attending Physician	Center for Comprehensive Health Practice, New York, NY	1992-97
Assistant Attending Physician	NewYork-Presbyterian Hospital	2008-22
Associate Attending Physician	NewYork-Presbyterian Hospital	2022-24
Medical Staff Consultant	Hospital for Special Surgery, New York, NY	2008-24

E. LICENSURE, BOARD CERTIFICATION

Licensure:

State	Number	Dates
Italian licence to practice medicine	4426	31/12/86
New York state licence	233172	06/30/04-
DEA number	BS9693260 BX9693269 (buprenorphine prescriber)	
NPI number:	1043364631	

Board Certification:

Full Name of Board	Dates
Italian Board of Medicine and Surgery	1986
American Board of Internal Medicine	2006-
American Board of Internal Medicine/ Infectious Diseases	2007-

F. HONORS AND AWARDS

Name of award	Organization	Date
M.D., <i>Summa Cum Laude</i>	Catholic University Medical School, Rome, Italy	1986
Competitive Award on Preventive Health	Ministero Della Sanita', Italy	1987
Lilly-Humulin award	Catholic University Medical School, Rome, Italy	1989
Award for HIV research	Istituto Superiore di Sanita' Rome, Italy	1999
Young Investigator award	Stony Wold – Herbert Fund	2006
Top Cited Paper Award 2006-2008	Journal of Hepatology	2009
Affinito-Steward Leadership Award	President's Council of Cornell Women (PCCW)	2014

Advancement to Fellow	Infectious Disease Society of America	2018
Spokeperson	Infectious Disease Society of America	2020-
Chair Steering Research Committee PRESCO study	Brin Foundation/Verily	2021
Election to Councilor	Infectious Diseases Society of New York	2021-2023
ID Week Visiting Professor	Infectious Disease Society of America	2021
Certificate of Appreciation for outstanding contributions and service to the Research Committee	Infectious Diseases Society of America	2023
Invited member	Sigma Xi Scientific Research Honor Society	2024
Vice President (path to President in 2025)	Infectious Diseases Society of New York	2024-
Selected for the 2025 Community of Leaders programs	Infectious Disease Leadership Institute, Infectious Disease Society of America	2025

I. PROFESSIONAL ORGANIZATIONS AND SOCIETY MEMBERSHIPS

Organization	Dates
Italian Medical Association	1986-
American Society for Virology (ASV)	1998-2012
Infectious Diseases Society of America (IDSA)	2006-
Infectious Disease Society of New York (IDSNY)	2006-
American Society for Microbiology (ASM)	2011-
International Society of Travel Medicine (ISTM)	2011-2019
International Society for Influenza and Other Respiratory Viruses (ISIRV)	2016-

J. EDUCATIONAL CONTRIBUTIONS

Didactic teaching:

Lectures:	Dates
Medical Students	
Lecture to second-year medical students: Health, Illness, and Disease II Infectious Diseases "Respiratory viral infections" (yearly)	2015-present
Lecture to second-year medical students: Health, Illness, and Disease II Infectious Diseases: Covid-19 physician panel "Covid-19 immune responses"	2020
Fellows	
Lecture to ID Fellows: Pre-travel consultation	2011
Lecture to ID Fellows NYP-Queens (yearly)	2020-
Clinic staff (Nurses, MDs, PA students, Social Workers) of the Vincent P. Dole Research and Treatment Institute for Opiate Dependency (part of the NYP ambulatory care network)	
In-service training lecture: "Hepatitis C diagnosis and treatment" (yearly)	2008-
In-service training lecture: "Covid Vaccines"	2020

Small Group Facilitator:

Dates

Medical Students

Health, Illness, and Disease II (Everyday Infectious Disease): Small group sessions on Infectious Diseases and Clinical Microbiology for second-year medical students (six 1.5-hour sessions per year).	2008-
Medicine, Patients and Society II: Tutor Patient physical exam and discussion/differential diagnosis of clinical findings six 2-hours sessions per year)	2008-10
Clinical teaching	Dates
Clinic preceptor of Physician Assistant students 2-3 clinic/week	2009-20
Clinic supervision/ training in travel medicine and clinical supervision of Nurse practitioners in the travel medicine clinic	2009-13
Clinic preceptor of fellows rotating in the travel medicine clinic (4 clinic/fellow/year)	2009-13
Infectious Diseases fellows inpatient consult service teaching attending	2009-
Addiction Medicine fellows, outpatient clinic teaching attending	2021

Administrative teaching leadership role:	Dates
Course Director for the CME seminar series: Community and Public Health Research Rounds (1 seminar/ month from October to May) (Organization, selection and introduction of the speakers, administrative issues)	2010-14

Community education or patient outreach

Our Voices, Strategica Communication (NYC): <i>Vaccino anti-covid tutto quello che c'e' da sapere (Education for Italian in NYC on COVID vaccines)</i>	30/11/2020
--	------------

L. CLINICAL PRACTICE, INNOVATION, and LEADERSHIP

Clinical Activities / Contributions	Dates
Attending Physician, Center for Comprehensive Health Practice, New York, NY	1992-95
Attending Physician, Vincent P. Dole Research and Treatment Institute for Opiate Dependency, New York Presbyterian hospital	2008-
Attending Physician on Infectious Diseases Teaching Consult Service, New York Presbyterian hospital	2008-

Clinical/Administrative Leadership

Administrative Activity	Dates
Medical Director for the travel medicine/ID associate clinic (Guided the transition of the clinic from paper-based to the computer-based EPIC system and the implementation of the Physician Quality Reporting System (PQRI). Participated in the selection/ hiring of clinic staff and nurse practitioners). Guided the training and supervision of nurses and nurse practitioners	2009-13

M. RESEARCH

Clinical Research Activities:

Active IRB protocols:

20-12023076 Salvatore, Mirella

Randomized double-blind, placebo-controlled pilot study of the efficacy and safety of baloxavir in combination with standard of

		care in stem cell transplant patients hospitalized for influenza 10/25/2022
20-03021645	Salvatore, Mirella	Viral characteristics and host responses to novel coronavirus SARS-2 infection and vaccination
19-11021069	Mason, Christopher	Rapid Diagnosis of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)
1506016280	Salvatore, Mirella	Epidemiological/ viral factors and influenza and other respiratory viral infection disease outcome 04/12/2022
1206012440	Crystal, Ronald	Phase I randomized, double-blind, placebo control study for an anti-cocaine vaccine 08/23/2022
1105011710	Soave, Rosemary	Infectious Complications of Immunosuppression
0910010689	Salvatore, Mirella	INSIGHT H1N1v Hospitalization Study (FLU 003): An International Observational Study to Characterize Hospitalized Adults with Influenza A - Pandemic H1N1 (H1N1v) 07/09/2022

Closed protocols:

1804019176	Salvatore, Mirella	Harnessing the blood transcriptome to study the effects of multiple vaccinations in travelers 12/16/2020
20-08022553	Salvatore, Mirella	Predictors of Severe COVID-19 Outcomes (PRESCO) 09/21/2022
20-04021761	Evering, Teresa	Establishment and Characterization of a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Cohort in Humans to Understand Disease Pathogenesis 07/13/2021
1501015825	Salvatore, Mirella	Longitudinal characterization of the respiratory microbiome diversity and host gene expression after influenza and other respiratory viral infections. 03/02/2018
1411015644	Salvatore, Mirella	Longitudinal characterization of the respiratory microbiome diversity and host gene expression during hematopoietic stem cell transplant (HSCT) and respiratory infections. 01/16/2018
1410015615	Small, Catherine	GS-US-218-1502: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS-5806 in Hematopoietic Cell Transplant (HCT) Recipients with Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract 12/18/2017
1410015586	Small, Catherine	GS-US-218-0108: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS-5806 in Hematopoietic Cell Transplant (HCT) Recipients with Respiratory Syncytial Virus (RSV) Infection of the Upper Respiratory Tract. 12/18/2017
1408015409	Small, Catherine	GS-US-218-1227 - A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS-5806 in Hospitalized Adults with Respiratory Syncytial Virus (RSV) Infection 10/09/2017
1403014933	Soave, Rosemary	DAS181-2-05: A Phase II, Randomized, Double-blind, Placebo controlled study to examine the effects of DAS181 in immunocompromised subjects with Lower Respiratory Tract

0910010688 Glesby, Marshall	Parainfluenza Infection on Supplemental Oxygen 10/24/2017
0306006211	INSIGHT Outpatient Study (FLU 002 Plus): An International Observational Study to Characterize Adults with Influenza or Other Targeted Respiratory Viruses 05/22/2017
	Beeder, Ann Community Health and Health Care Study. 04/27/2017

Closed IACUUC protocol

2009-045 Integrase-defective lentiviral based influenza vaccines (2009-2019)

Research Support:

Current Research Funding

Source:	National Institute of Allergy and Infectious Diseases (NIAID) 1R21AI182901-01
Project title:	The effects of immunosuppression on SARS-CoV-2 persistence, virus genetic diversity and clinical outcomes of COVID-19
Duration of support:	July 7, 2024-June 30, 2025
Role in Project	PI
The major goals of this project are:	<i>Assessing the effect host immune status and therapy on viral diversity and outcome</i>

Pending Research Funding

Source:	National Institutes of Health 1 R01 DA064066-01
Title:	A Systems Approach Towards Opioid Use Disorder, Neuro-Immune Interactions, and Vaccinations in Adults with HIV
Duration of support:	July 1, 2025-June 30, 2030
Role in Project	PI (Evering Co-PI)
The major goals of this project are:	Assessing the role relation between vaccination, opioid use and neuroinflammation in people with HIW

Source:	National Institutes of Health 1R01 RHL180875A
Title:	Fungal Drivers of Lung Inflammation
Duration of support:	Sept 1, 2024-Aug 30, 2026
Role in Project	Co-investigator (Iliyan D Iliev PI)
The major goals of this project are:	Assessing the role of gut mycobiome in lung inflammation due to allergic or infectious stimuli

Source:	CEIRS/NIH
Title:	<i>Immunosuppression as driver of influenza diversity, persistence, and outcome</i>
Duration of support:	June 1, 2025-July 30, 2027
Role in Project	PI
The major goals of this project are:	integrate patient data with immune profiling and deep sequencing to ascertain the effect of host immunity and therapeutics on influenza diversity within the host and disease outcome

Completed Research Support:

Source	National Institute of Allergy and Infectious Diseases (NIAID): NIH 5T32AI007623-09
Project Title	Pathogenesis of Infectious Diseases Training Program
\$ Amount	N/A
Duration (MM/YY)	July 2003 - June 2004
Role in Project	Trainee (M. Klotman PI)

Source	Stony Wold – Herbert Fund Young investigator
Project Title	Inhibition of Influenza Virus Replication by Alpha-defensin
Duration (MM/YY)	July 2006-June 2009
Role in Project	PI

Source	National Institute of Allergy and Infectious Diseases
Project Title	Award ID: HHSN272200900001/2/3I Task Order N.1
Duration (MM/YY)	Influenza Combination Antiviral Focus Group
Role in Project	11/2009-11/2010
	PI, Subaward

Source	National Institute of Allergy and Infectious Diseases
Project Title	(NIAID): Award ID: 5 R21 AI073926
Duration (MM/YY)	Integrase-defective Lentiviral Based Influenza Vaccines
Role in Project	July 2009 - September 2012
	PI

Source	Weill Cornell CTSC Pilot award
Project Title	Immune Responses to Influenza Vaccination in Opioid Users
Duration (MM/YY)	July 2010- June 2012
Role in Project	PI

Source	Feldstein Medical Foundation
Project Title	Targeted Vector Delivery for Rapid Protection from Infectious Disease
Duration (MM/YY)	July 2012-June 2013
Role in Project	PI

Source	National Institute on Drug Abuse (NIDA) 5R01DA029512
Project Title	Subcontracted by: SUNY Downstate Medical Center
Duration (MM/YY)	Integrated vs. Separate Care for Hepatitis C, Substance Abuse, and HIV Prevention
Role in Project	4/2010-1/2017
	Co-investigator (A. Beeder PI)

Source	Einaudi Foundation
Project Title	Development of a Research Network with Singapore for the study of Chikungunya and other emerging viral infections
Duration (MM/YY)	7/2014-6/2016
Role in Project	PI

Source	PCCW Affinito-Stewart Grant
Project Title	Integrase-Defective Lentiviral-Based Influenza Vaccine expressing NP. Role of NP-specific antibody and CD4+/CD8+ T cell subsets in protection
Duration (MM/YY)	7/2014-6/2016
Role in Project	PI
Source	The Gladys and Roland Harriman Foundation
Project Title	Integrase Defective Lentiviral Vectors for Antibody Delivery against Influenza
Duration (MM/YY)	May 2016-April 2017
Role in Project	PI
Source	Ansun BioPharma, Inc.
Project Title	Clinical trial: DAS181-2-05: A Phase II, Randomized, Double-blind, Placebo controlled study to examine the effects of DAS181 in immunocompromised subjects with Lower Respiratory Tract Parainfluenza Infection on Supplemental Oxygen
Duration (MM/YY)	2015- 2017
Role in Project	Co-investigator (R. Soave PI)
Source/PI	Gilead Sciences, Inc.
Project Title	Clinical trial: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS-5806 in Hematopoietic Cell Transplant (HCT) Recipients with Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract
Duration (MM/YY)	2015- 2017
Role in Project	Co-investigator (R. Soave PI)
Source	National Institute on Drug Abuse (NIDA)
Project Title	1 U01 DA033835 Disrupted Adenovirus Serotype 5-based Anti-cocaine Vaccine
Duration (MM/YY)	8/2012-5/2018
Role in Project	Co-investigator (R. Crystal PI)
Source	National Institute of Allergy and Infectious Diseases
Project Title	Integrase Defective Lentiviral Vectors for Antibody Delivery against Influenza 1R21 AI124141
Duration (MM/YY)	July 2016- June 2019
Role in Project	PI
Source	Glaxo SmithKline
Project Title	207266 / A Study to Evaluate the Viral RNA Copy Number of Influenza A and B Viruses in Symptomatic Adults by Use of Three Different Specimen Collection Techniques
Duration (MM/YY)	2017
Role in Project	Site PI

Source:	International Society of Travel Medicine
Project title:	Harnessing the Blood Transcriptome to Study the Effects of Multiple Vaccinations in Travelers
Duration of support:	2018- 2021
Role in Project	PI
The major goals of this project are:	<i>Studying the effect of combined vaccines administration versus the single vaccine at level protein expression.</i>
Source:	National Institute on Drug Abuse (NIDA)
Project title:	1 U01 DA048524 Clinical Assessment of Anti-cocaine Vaccine dAdGNE in Cocaine Addicts
Duration of support:	2019-2022
Role in Project	Co-investigator (R. Crystal PI)
The major goals of this project are:	<i>Testing a novel viral vector platform-based vaccine for cocaine addiction in human. Dose-escalation study</i>
Source:	Genentech (investigator-initiated study)
Project title:	Randomized Double-blind, Placebo-controlled Pilot Study of the Efficacy and Safety of Baloxavir in Combination with Standard of Care in Stem Cell Transplant Patients Hospitalized for Influenza NCT05170009
Duration of support:	July 1, 2022-June 30, 2024
Role in Project	PI
Your percent (%) effort:	Per hour
The major goals of this project are:	<i>Assessing the effects on viral load, emergence of viral variants and clinical effectiveness of a novel influenza combination therapy in Stem Cell Transplant Patients Hospitalized for Influenza</i>
Source:	National Institute of Health
Project title:	Respiratory Virus Hospitalization Study (INSIGHT study FLU 003 Plus NCT01056185
Duration of support:	September 1, 2022 - August 30, 2024
Role in Project	Site PI
The major goals of this project are:	<i>Longitudinal Multicenter samples collection from patients with influenza of different severity</i>
Source:	Sergey Brin Family Foundation / Verily
Project title:	Predictors of Severe COVID-19 Outcomes (PRESCO)
Duration of support:	December 1, 2020 - March 30, 2022
Role in Project	Site PI
The major goals of this project are:	<i>Longitudinal Multicenter samples collection from patients with Covid-19 of different severity for the development of biomarkers predictive of severity and of long term Covid-19 complications (PASC)</i>

N. MENTORING

Name	Rosella Petraroli
Site/Position	PhD student, Istituto Superiore di Sanita' Rome
Mentoring Period	1992-95
Project/Accomplishments**,	Published several papers on genetic mutation and predisposition to prion diseases (ref# 12, 13,14, 15, 16)

<i>Current Position</i>	<i>EMEA Market Development Leader - Clinical Next Generation Sequencing Division at Thermo Fisher Scientific</i>
<i>Type of Supervision</i>	<i>Research</i>
<i>Name</i>	Skanda Kadirgamar
<i>Site/Position</i>	Columbia Preparatory School Student
<i>Mentoring Period</i>	2005-06
<i>Project/Accomplishments**</i> ,	Learned basic laboratory and cell culture techniques
<i>Current Position</i>	UNKN
<i>Type of Supervision</i>	<i>Research</i>
<i>Name</i>	Zuleika Michelini PhD
<i>Site/Position</i>	Visiting summer student, Mount Sinai School of Medicine
<i>Mentoring Period</i>	Summer 2007
<i>Project/Accomplishments**</i> ,	Coauthor to ref#28
<i>Current Position</i>	Senior researcher, Istituto Superiore di Sanita'
<i>Type of Supervision</i>	<i>Research</i>
<i>Name</i>	Arnaud Drouin, MD
<i>Site/Position</i>	postdoctoral fellow
<i>Mentoring Period</i>	8/2009-6/10
<i>Project/Accomplishments**</i> ,	Accepted into Pathology Residency
<i>Current Position</i>	Adjunct Assistant professor, Tulane University
<i>Type of Supervision</i>	<i>Clinical/Research</i>
<i>Name</i>	Dahlene Fusco, MD,
<i>Site/Position</i>	ID fellow (co-mentor)
<i>Mentoring Period</i>	7/2009-6/10
<i>Project/Accomplishments**</i> ,	Her project was published in <i>Vaccine</i> (ref #25)
<i>Current Position</i>	<i>Assistant Professor, Tulane University</i>
<i>Type of Supervision</i>	<i>Influenza Research</i>
<i>Name</i>	Ekatherina Moroz, MD
<i>Site/Position</i>	postdoctoral fellow
<i>Mentoring Period (mm/yyyy-mm/yyyy)</i>	2010-12
<i>Project/Accomplishments**</i> ,	Obtained the CTSC certificate in Clinic Investigation and her work was published in <i>Vaccine</i> (ref #30)
<i>Current Position</i>	Senior Application Scientist
<i>Type of Supervision</i>	Protein Fluidics, Inc. · Full-time <i>Research</i>
<i>Name</i>	Judith Fontana, PhD
<i>Site/Position</i>	postdoctoral fellow
<i>Mentoring Period</i>	2010-14
<i>Project/Accomplishments**</i> ,	Presented to several national conferences including to the American Society for Virology where she was awarded a Travel Grant, obtained a fellowship form the Stony Wold-Herbert Fund (renewed twice. Published papers Ref #27, 28, 38 and book chapter 7)
<i>Current Position</i>	Research Scientist at New York University
<i>Type of Supervision</i>	<i>Research</i>
<i>Name</i>	Zuleika Michelini PhD

<i>Site/Position</i>	Visiting postdoctoral fellow
<i>Mentoring Period (mm/yyyy-mm/yyyy)</i>	2016
<i>Project/Accomplishments**</i> ,	Abstract presented at the Options X for the Control of influenza meeting, published first author paper on <i>Viruses</i>
<i>Current Position</i>	Senior researcher, Istituto Superiore di Sanita'
<i>Type of Supervision</i>	<i>Research</i>
<i>Name</i>	JianJun Yang, MS
<i>Site/Position</i>	Technician 2
<i>Mentoring Period (mm/yyyy-mm/yyyy)</i>	2016-2019
<i>Project/Accomplishments**</i> ,	Co-author in #38, Submitted #2, in preparation #1)
<i>Current Position</i>	Technician 2
<i>Type of Supervision</i>	<i>Research</i>
<i>Name</i>	Khin Pyai, MD
<i>Site/Position</i>	Research Associate
<i>Mentoring Period</i>	Spring 2017-June 2020
<i>Project/Accomplishments**</i> ,	Presented abstract at IDWeek 2018, won award for the poster among Burmese trainees. Accepted into Internal Medicine Residency
<i>Current Position</i>	Internal Medicine Resident
<i>Type of Supervision</i>	<i>Clinical/Research</i>
<i>Name</i>	Emily Coskun, MD
<i>Site/Position</i>	Resident in Internal Medicine
<i>Mentoring Period (mm/yyyy-mm/yyyy)</i>	2019-2021
<i>Project/Accomplishments**</i> ,	Presented abstract to the Internal Medicine Research Retreat, the American society of haematology national meeting, (manuscript in preparation)
<i>Current Position</i>	Fellow, Columbia University
<i>Type of Supervision</i>	<i>Research</i>
<i>Name</i>	Brian Chernak, MD
<i>Site/Position</i>	Resident in Internal Medicine
<i>Mentoring Period (mm/yyyy-mm/yyyy)</i>	2019-2021
<i>Project/Accomplishments**</i> ,	Presented abstract to the American society of hematology national meeting, and he was awarded an Abstract Achievement Award and to the Internal Medicine Research Retreat (manuscript in preparation)
<i>Current Position</i>	Fellow, WCM
<i>Type of Supervision</i>	<i>Research</i>

Other mentoring activities *Describe activity; indicate dates.*

<i>Name</i>	Samantha Jacobs, MD
<i>Site/Position</i>	ID fellow
<i>Mentoring Period</i>	May-June 2014
<i>Project/Accomplishments**</i> ,	Master Clinical and Translational Investigation
<i>Current Position</i>	<i>Assistant Professor, Mount Sinai</i>
<i>Type of Supervision</i>	Expert Evaluator, Examination Committee for CTSC Master Thesis
<i>Name</i>	Arial Marciscano, MD
<i>Site/Position</i>	Assistant Professor, Division of Radiation Oncology

<i>Mentoring Period</i>	2020
<i>Project/Accomplishments**</i> ,	presented abstract at American Society of Radiation Oncology Annual Meeting
<i>Type of Supervision (Research, clinical, teaching, leadership)</i>	Mentor for the NIH Spore grant (submitted) for the Influenza research section of the project
<i>Name</i>	Shenghao Tan, PhD
<i>Site/Position</i>	PhD, Cornell Ithaca bioengineering school
<i>Mentoring Period (mm/yyyy-mm/yyyy)</i>	Summer 2021
<i>Project/Accomplishments**</i> ,	NA
<i>Current Position</i>	same
<i>Type of Supervision (Research, clinical, teaching, leadership)</i>	Clinical/research summer mentor in training program

O. INSTITUTIONAL ADMINISTRATIVE ACTIVITIES

<i>Name of Committee</i>	<i>Role</i>	<i>Dates</i>
Substance Use Disorder/Opioid workgroup Function: Review opioid prescription and advise on opioid treatment resources at New York Presbyterian Hospital/Weill Cornell Medicine	Member	2017-18
General Faculty Council , Weill Cornell Medicine Representative for Department of Medicine full time faculty– Divisions of ID, Allergy, Rheumatology, Clinical Epidemiology, Public Health, Geriatric	Member	2019-22
Research, Clinical Affairs and Benefits Subcommittee of the General Faculty Council	Member	2019-present

K. EXTRAMURAL PROFESSIONAL RESPONSIBILITIES

Service on Boards and/or Committees

<u>Name of Committee</u>	<u>Role</u>	<u>Organization Institution/Location</u>	<u>Dates</u>
Regional			
PhD thesis defense, Jennifer Couret	External Committee Member	Public Health Research Institute, University of Medicine and Dentistry of New Jersey	2017
PhD thesis proposal Katherine Evelyn Elizabeth Johnson	External Committee Member	New York University	2018-2023
Infectious Diseases Society of New York (IDSNY)	Councilor	Infectious Diseases Society of New York, New York	2021-2023
Infectious Diseases Society of New York (IDSNY)	Vice President (then President Elect, President, Past President)	Infectious Diseases Society of New York, New York	2024-2027

National

Influenza Research Collaboration (IRC)-Combination Antiviral Focus Group	Member	National Institutes of Health - National Institute of Allergy and Infectious Diseases (NIH-NIAID)	2009-2010
Research Committee	Member	Infectious Diseases Society of America (IDSA)	2019-2023
Continuing Education Subcommittee	Member	Infectious Diseases Society of America (IDSA)	2024-2027

International

Research and Awards Committee	Member	International Society of Travel Medicine	2017-2021
-------------------------------	--------	--	-----------

Grant Reviewing/Study Sections

<u>Role(s)</u>	<u>Organization Name</u>	<u>Dates</u>
Grant Reviewer	Swiss National Science Foundation	6/2010
Grant Reviewer	NIH/NAID Scientific Review Panel, NIH Loan Repayment Program	6/2014
Abstract Reviewer	Translational Science Meeting, Washington DC	6/2015
Pandemic Influenza Scenario Reviewer	World Health Organization (WHO)	12/2016
Grant Reviewer	Swiss National Science Foundation	7/2017
Grant Reviewer	International Society of Travel Medicine	2018-21
Abstract Evaluator	Du Vigneaud Memorial Research Symposium for Graduate Students Research, Weill Cornell Medicine	2016-20
Grant Reviewer	NIH/NAID Scientific Review Panel, Special emphasis panel RFA AI-17-037 Immunity in the elderly	7/2018
Abstract reviewer	ID Week 2020 (Infectious Disease Society of America Annual Meeting)	6/2020
Grant Reviewer	NIH/NAID Scientific Review Panel ZAI1 JHM-X (S3) Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)	6/2020
Grant Reviewer	NIH/NAID Scientific Review Panel ZAI1 LRW (J2) Rapid Investigation of Severe Acute Respiratory Syndrome	11/2020

	Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)	
Abstract reviewer	ID Week 2021, (Infectious Disease Society of America Annual Meeting)	6/2021
Grant Reviewer	NIEHS P30 Pilot Grant Application	2/2023
Grant Reviewer	Swiss National Science Foundation Bridge – Discovery grant	7/2023
Grant Reviewer	NIH/NAID Scientific Review Special emphasis panel ZAI1 VSR-I (S1)1 RFA 22-060 Immunity in older adults	8/2023
Grant Reviewer	Emerging Clinician Scientist Awards Health Research Board (HRB), Ireland.	4/2024
Grant Reviewer	NIH/NAID Scientific Review Special Emphasis Panel (ZAI1-RD-D-S2) PA24-141 R13 NIH Support for Conferences and Scientific Meetings	6/2024
Grant Reviewer	NIH/NAID Scientific Review Special Emphasis Panel ZAI1-SAG-M-M1-U01	2/2025

Editorial Activities

Editorial Board Membership

- Editorial Board and Associate Editor: Frontiers in Medicine 2019- present
- Editorial Board and Associate Editor: Frontiers in Public Health, section of Infectious Diseases – Surveillance, Prevention and Treatment
- Editorial Associate Editor: Vaccine 2019- present

Journal Reviewing/ad hoc reviewing (selected)

- *Annals of Internal Medicine*
- *Annals of Hematology*
- *Expert Opinion on Biological Therapy*
- *Frontiers in Immunology*
- *Journal of Virology*
- *Influenza and Other Respiratory Viruses*
- *International Journal of Molecular sciences*
- *International Journal of Environmental Research and Public Health*
- *Microbiome*
- *Nutrients*
- *Open Forum Infectious Diseases*
- *PlosOne*
- *The ISME Journal*
- *Seminars in Immunology*
- *Scientific Reports*
- *Translational Research*
- *Tropical Medicine and Infectious Disease*

- *Vaccine*
- *Vaccines*
- *Virology Journal*
- *Virus Research*
- *Viruses*

L. INVITATIONS TO SPEAK/PRESENT

Regional <u>Title</u>	<u>Institution/Location</u>	<u>Dates</u>
Novel therapies for influenza	Memorial Sloan Kettering Cancer Center, New York, NY	2010
Mucosal immunity and immunization	Hot Topics in Infectious Diseases, NYU Biology Graduate School, New York	5/23/2016
Fighting the Flu: Advances in Influenza Treatment	Practicing Clinicians Exchange (PCE) Symposia Series CME educational series for medical professional organized by the Boston University), Newark, NJ	6/23/2018
Influenza 2019: Emerging Vaccination and Therapeutic Strategies	Advanced Topics in Infectious Diseases, Memorial Sloan Kettering Cancer Center: New York, NY	3/15/2019
Integrase- defective lentiviral based approach to influenza vaccine	Department of Microbiology, Biochemistry & Molecular Genetics, Public Health Research Institute, UMDNJ, Newark, NJ	9/6/2019
Influenza prevention and treatment: current approaches and emerging concepts”	Medical Grand Rounds NYPH Queens, New York, NY	10/16/2019
Harnessing human Covid-19 Cohorts and immune-omics integration for disease predictions	Cornell, Ithaca & Weill Cornell Medicine COVID-19 Summit	11/5/2020
Vaccines for prevention of influenza and COVID-19	NYPH Queens Infectious Disease Seminar Series, New York, NY	12/30/2020
Overcoming Challenges in the treatment of Influenza	Flushing Hospital Medical Center, Department of Medicine Grand Rounds:	2/9/2020
Flu Season 2021: What to Expect & How to Prepare	New York Presbyterian Fall 2021 Health and Wellness Seminar Series	10/5/2021
Metabolic and immune markers for precise monitoring of COVID-19 severity and treatment	University of Rochester Medical Center, Allergy, Immunology and Rheumatology Grand Rounds	11/11/2021
Covid-19: Immunological and metabolic findings	NYP Queens Infectious Disease Seminar Series	11/19/2021

COVID-19: Treatment Options and Therapeutic Challenges	New York-Presbyterian Queens Infectious Disease Lecture Series	11/18/2022
Update on 2022 - 2023 seasonal Influenza	WCMA primary Care division, Weill Cornell Medicine	12/7/2022
Persistent SARS-CoV2 infection of the immunocompromised host. From bedside to bench and back	Department of Medicine, Icahn School of Medicine at Mount Sinai, NY, NY	9/10/2024
Emergence of resistance to COVID-19 treatments in the immunocompromised host. From bedside to bench and back	Infectious Disease Grand Round Robert Wood Johnson Medical School New Brunswick, NJ	10/29/2024
TBD	Infectious Disease Grand Round New York University New York,	12/13/2024
National		
<u>Title</u>	<u>Institution/Location</u>	<u>Dates</u>
Fighting the Flu: Advances in Influenza Treatment	Practicing Clinicians Exchange (PCE) 2018 Symposia Series (CME educational series for medical professional organized by the Boston University), Denver, CO	6/2/2018
Fighting the Flu: Advances in Influenza Treatment	Practicing Clinicians Exchange 2018 Symposia Series, CME educational series for medical professional organized by the Boston University), held in Cambridge, MA	11/3/2018
Overcoming challenges in the treatment of Influenza	Peerview Institute for Medical Education, CME live seminar series	11/12/2020
Responding to COVID-19 Variants	Consultant 360 Webinar series, COVID-19 Research Briefs	3/15/2021
Integrated omics analysis of host responses and COVID-19 severity	System Genomic Section, National Institute of Allergy and Infectious Disease (NIAID)	11/16/21
Novel therapies for COVID-19 and influenza	Johns Hopkins School of Medicine, Clinical Pharmacology Grand Rounds	4/27/2022
Flu Season 2022: What to Expect and How to Prepare.	Weill Cornell Medicine Wellness Series	12/8/2022
Emergence of resistance to COVID-19 treatments in the immunocompromised host	Infectious Disease Grand Round University of Maryland School of Medicine Baltimore, MA	11/10/2024
International		
<u>Title</u>	<u>Institution/Location</u>	<u>Dates</u>
Updates on Influenza	Salzburg Seminar in Infectious Diseases, Salzburg, Austria	5/10/2019
Vaccines in the immunocompetent host	Salzburg Seminar in Infectious Diseases: Salzburg Austria	5/8/2019

Preventing a twindemic: Advances and challenges in flu and COVID-19 vaccine development	Weill Cornell Qatar Covid-19 Clinical webinar series	12/02/2020
Covid-19: the NYC experience and scientific advances	Federal University of Health Sciences of Porto Alegre, Global Health lecture series	11/9/2021
Precise monitoring of Covid-19 severity and treatment	8th European Scientific Working Group on Influenza (ESWI) Conference -Hot Topics on Influenza, RSV and Covid-19	12/5/21
One Health	Congresso Internazionale Corso 1980-1986 Università Cattolica del Sacro Cuore - Roma	9/20/2024
Emergence of resistance to COVID-19 treatments in the immunocompromised host	Options XII for the control of Influenza, Brisbane	10/1/2024

Expert Interviews:

AOL.com World's Worst Travel Diseases (And How To Avoid Them)	2011
Men's Health Magazine UK What to include in a vacation first aid kit	2013
Health Magazine What to include in a vacation first aid kit	2013
EverydayHealth.com Sanjay Gupta What travelers need to know about virus outbreaks https://www.everydayhealth.com/sanjay-gupta/what-travelers-need-to-know-about-virus-outbreaks.aspx	6/5/2013
Managed Health Care Dan Cook Educating Patients on Flu Vaccine Importance http://www.managedhealthcareconnect.com/content/educating-patients-flu-vaccine-importance	6/5/2017
Healio Infectious Disease News Vaccine refusal: What are the best ways to overcome it? http://www.healio.com/internal-medicine/infectious-diseases/news/print/infectious-disease-news/%7B34ed9aac-0831-41a0-8810-4efa8aff38c8%7D/vaccine-refusal-what-are-the-best-ways-to-overcome-it	5/2017
US News World Report Michael O. Schroeder Before You Travel: Have You Gotten Recommended Vaccines? <i>Take precautions if you're planning to go abroad.</i> http://health.usnews.com/health-care/patient-advice/articles/2017-07-04/before-you-travel-have-you-gotten-recommended-vaccines	7/4/2017
The New York Times Alexandra S. Levine New York Today: Messy Weather and Flu Facts	1/17/2018

https://www.nytimes.com/2018/01/17/nyregion/new-york-today-messy-weather-and-flu-facts.html?rref=collection%2Fcolumn%2Fny-today-daily-briefings&action=click&contentCollection=nyregion&region=stream&module=stream_unit&version=latest&contentPlacement=1&pgtype=collection&_r=1	
The Village Voice Mary Bakija As Flu Rages, Food Workers Resist Calling in Sick https://www.villagevoice.com/2018/02/15/as-flu-rages-food-workers-resist-calling-in-sick/	2/15/2018
The New York Times Alexandra S. Levine New York Today: Flu Season returns https://static.nytimes.com/email-content/UR_6667.html?nlid=28025736 also referenced by Fox News https://www.foxnews.com/health/should-i-get-the-flu-shot-what-to-know-about-the-2018-19-flu-season	10/16/2018
NBC health news Shamard Charles What is a cruise ship quarantine? St. Lucia liner detained after measles outbreak https://www.nbcnews.com/health/health-news/what-quarantine-st-lucia-cruise-ship-detained-after-measles-outbreak-n1000841 Also referenced by: The Salon https://www.salon.com/2019/05/02/there-is-a-scientology-cruise-ship-and-it-has-just-been-quarantined-due-to-measles/ St Lucia News online: https://www.stlucianewsonline.com/doctors-explain-medical-quarantine-after-saint-lucia-cruise-ship-detained-due-to-measles-outbreak/	5/1/2019
Our Voices, Strategica Communication (NYC): <i>Vaccino anti-covid tutto quello che c'e' da sapere (Education for Italian in NYC on COVID vaccines)</i>	30/11/2020
NYP Health Matters What to Know About the New Coronavirus Variants https://healthmatters.nyp.org/what-to-know-about-the-new-coronavirus-variants/	2/2021
Medscape: What we know and what we do not know about virus variants https://www.medscape.com/viewarticle/944508	1/21/2021
Health Karen Pallarito Can You Safely Hang Out with Unvaccinated Friends? Here's What Doctors Recommend https://www.health.com/condition/infectious-diseases/coronavirus/can-you-hang-out-with-unvaccinated-friends?fbclid=IwAR0A91qG6ibuvPGri2WUWB58gESS-TuUVp-XliUSHWR2qk-gFCC5s5yOOns	7/21/21

Radio

NY Public Radio Please Explain this flu season	2/23/2018
---	-----------

https://www.wnyc.org/story/please-explain-flu-season/	
---	--

Podcasts

Infectious Disease Society of America Media Briefing: Coronavirus Variants https://www.idsociety.org/multimedia/videos/idsa-media-briefing-coronavirus-variants/	1/21/2021
Infectious Disease Society of America COVID-19 Podcast: COVID-19: Emerging Variants and the race to Vaccinate https://www.idsociety.org/multimedia/podcasts/covid-19-emerging-variants-and-the-race-to-vaccinate/	2/6/2021
VuMedi (medical education website): Will Emerging Coronavirus Variants Affect Overall Mortality? What Can We Do to Stay Ahead of the Evolving Scenario of More Transmissible Variants? https://www.vumedi.com/video/will-emerging-coronavirus-variants-affect-overall-mortality-what-can-we-do-to-stay-ahead-of-evolving/	2/1/2021
Science Writers of New York (SWINY): COVID-19 Variants and Vaccines: A Virtual Conversation with Dr. Mirella Salvatore https://www.youtube.com/watch?v=Sy_OYPX0qlw	2/3/2021

G. BIBLIOGRAPHY

OrcID: orcid.org/0000-0002-8296-0376

H index: 41

Citation 4192 (google scholar)

a. Peer-Reviewed Original Research Articles:

1. Manna R, **Salvatore M**, Pantoli D, Vecchio FM, Greco AV, Carosella L, Schiavino D, Ghirlanda G. Malignant histiocytosis: report of three cases. Br J Clin Pract. 1988 Feb;42(2):82-6. PubMed PMID: 3179178.
2. Manna R, **Salvatore M**, Scuderi F, Papa G, Marietti G, Greco AV, Ghirlanda G, Gambassi G. Negative correlation between ICA persistence and beta cell restoration after IDDM diagnosis. Diabetes Res. 1988 Nov;9(3):101-3. PubMed PMID: 3072142.
3. Manna R, **Salvatore M**, Amato S, Ghirlanda G, Scuderi F, Greco AV. HLA antigens and islet cell antibodies are useful for the identification of type 1 diabetes high risk subjects. Acta Med Romana. 1988; 3:340-344.
4. Manna R, **Salvatore M**, Di Leo MA, Scuderi F, Greco AV, Ghirlanda G, Gambassi G. Relationship between urinary neopterin excretion and islet cell antibodies in type 1 (insulin-dependent) diabetes. Diabetes Res. 1991 May;17(1):33-6. PubMed PMID: 1816978.
5. Magalini S.C., Nanni G., Agnes S., Avolio A.W., **Salvatore M**, Manna R., Castagneto M. Neopterin, amyloid A, C-reactive protein, gamma-interferon, and interleukin-2 receptor in diagnosis of posttransplantation rejection. Transplant Proc. 1991; 23(4):2267-8.
6. Magalini SC, Nanni G, Agnes S, Avolio AW, **Salvatore M**, Manna R, Migliore A, Liang L, Micantonio L, Ponte E, Marietti G, Pantanella G, La Valle C, Greco AV, Ghirlanda G. Ridotta secrezione insulinica rivelata dall'IVGTT nei consanguinei di primo grado di pazienti affetti da diabete insulino dipendente. Giornale Italiano di Diabetologia 1990 1:9-13.

7. Pocchiari M, **Salvatore M**, Ladogana A, Ingrosso L, Xi YG, Cibati M, Masullo C. Experimental drug treatment of scrapie: a pathogenetic basis for rationale therapeutics. *Eur J Epidemiol.* 1991 Sep;7(5):556-61. PubMed PMID: 1761115.
8. Ladogana A, Casaccia P, Ingrosso L, Cibati M, **Salvatore M**, Xi YG, Masullo C, Pocchiari M. Sulphate polyanions prolong the incubation period of scrapie-infected hamsters. *J Gen Virol.* 1992 Mar;73 (Pt 3):661-5. PubMed PMID: 1372039.
9. Pocchiari M, Masullo C, **Salvatore M**, Genuardi M, Galgani S. Creutzfeldt-Jakob disease after non-commercial dura mater graft. *Lancet.* 1992 Sep 5;340(8819):614-5. PubMed PMID: 1355193.
10. Pocchiari M, **Salvatore M**, Cutruzzolá F, Genuardi M, Allocatelli CT, Masullo C, Macchi G, Alemá G, Galgani S, Xi YG. A new point mutation of the prion protein gene in Creutzfeldt-Jakob disease. *Ann Neurol.* 1993 Dec;34(6):802-7. PubMed PMID: 7902693.
11. Masullo C, **Salvatore M**, Macchi G, Genuardi M, Pocchiari M. Progressive dementia in a young patient with a homozygous deletion of the PrP gene. *Ann N Y Acad Sci.* 1994 Jun 6;724:358-60. PubMed PMID: 8030960.
12. **Salvatore M**, Genuardi M, Petraroli R, Masullo C, D'Alessandro M, Pocchiari M. Polymorphisms of the prion protein gene in Italian patients with Creutzfeldt-Jakob disease. *Hum Genet.* 1994 Oct;94(4):375-9. PubMed PMID: 7927332.
13. **Salvatore M**, Seeber AC, Nacmias B, Petraroli R, D'Alessandro M, Sorbi S, Pocchiari M. Apolipoprotein E in sporadic and familial Creutzfeldt-Jakob disease. *Neurosci Lett.* 1995 Oct 20;199(2):95-8. PubMed PMID: 8584252.
14. **Salvatore M**, Pocchiari M, Cardone F, Petraroli R, D'Alessandro M, Galvež S, Brown P, Macchi G, Fieschi C, Colosimo C. Codon 200 mutation in a new family of Chilean origin with Creutzfeldt-Jakob disease. *J Neurol Neurosurg Psychiatry.* 1996 Jul;61(1):111-2. PubMed PMID: 8676137;
15. Barbanti P, Fabbrini G, **Salvatore M**, Petraroli R, Cardone F, Maras B, Equestre M, Macchi G, Lenzi GL, Pocchiari M. Polymorphism at codon 129 or codon 219 of PRNP and clinical heterogeneity in a previously unreported family with Gerstmann-Sträussler-Scheinker disease (PrP-P102L mutation). *Neurology.* 1996 Sep;47(3):734-41. PubMed PMID: 8797472.
16. **Salvatore M**, Seeber AC, Nacmias B, Petraroli R, Sorbi S, Pocchiari M. Alpha1 antichymotrypsin signal peptide polymorphism in sporadic Creutzfeldt-Jakob disease. *Neurosci Lett.* 1997 May 16;227(2):140-2. PubMed PMID: 9180223.
17. **Salvatore M**, Morzunov S, Schwemmler M, Lipkin WI. Borna disease virus in brains of North American and European people with schizophrenia and bipolar disorder. Borna disease Study Group. *Lancet.* 1997 Jun 21;349(9068):1813-4. PubMed PMID: 9269221.
18. Schwemmler M*, **Salvatore M***, Shi L, Richt J, Lee CH, Lipkin WI. Interactions of the borna disease virus P, N, and X proteins and their functional implications. *J Biol Chem.* 1998 Apr 10;273(15):9007-12. PubMed PMID: 9535888. ***equal contribution**
19. Talon J, **Salvatore M**, O'Neill RE, Nakaya Y, Zheng H, Muster T, García-Sastre A, Palese P. Influenza A and B viruses expressing altered NS1 proteins: A vaccine approach. *Proc Natl Acad Sci U S A.* 2000 Apr 11;97(8):4309-14. PubMed PMID: 10725408.
20. Basler CF, Reid AH, Dybing JK, Janczewski TA, Fanning TG, Zheng H, **Salvatore M**, Perdue ML, Swayne DE, García-Sastre A, Palese P, Taubenberger JK. Sequence of the 1918 pandemic influenza virus nonstructural gene (NS) segment and characterization of recombinant viruses bearing the 1918 NS genes. *Proc Natl Acad Sci U S A.* 2001 Feb 27;98(5):2746-51. PubMed PMID: 11226311.
21. **Salvatore M**, Basler CF, Parisien JP, Horvath CM, Bourmakina S, Zheng H, Muster T, Palese P, García-Sastre A. Effects of influenza A virus NS1 protein on protein expression: the NS1 protein enhances translation and is not required for shutoff of host protein synthesis. *J Virol.* 2002 Feb;76(3):1206-12. PubMed PMID: 11773396.

22. Geiss GK*, **Salvatore M***, Tumpey TM, Carter VS, Wang X, Basler CF, Taubenberger JK, Bumgarner RE, Palese P, Katze MG, García-Sastre A. Cellular transcriptional profiling in influenza A virus-infected lung epithelial cells: the role of the nonstructural NS1 protein in the evasion of the host innate defense and its potential contribution to pandemic influenza. *Proc Natl Acad Sci U S A*. 2002 Aug 6;99(16):10736-41. PubMed PMID: 12149435. *** equal contribution**
23. Bräu N, **Salvatore M**, Ríos-Bedoya CF, Fernández-Carbia A, Paronetto F, Rodríguez-Orengo JF, Rodríguez-Torres M. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. *J Hepatol*. 2006 Jan;44(1):47-55. Epub 2005 Jul 27. PubMed PMID: 16182404.
24. **Salvatore M**, Garcia-Sastre A, Ruchala P, Lehrer RI, Chang T, Klotman ME. alpha-Defensin inhibits influenza virus replication by cell-mediated mechanism(s). *J Infect Dis*. 2007 Sep 15;196(6):835-43. Epub 2007 Aug 10. PubMed PMID: 17703413.
25. Fusco D, Liu X, Savage C, Taur Y, Xiao W, Kennelly E, Yuan J, Cassileth B, **Salvatore M**, Papanicolaou GA. Echinacea purpurea aerial extract alters course of influenza infection in mice. *Vaccine*. 2010 May 21;28(23):3956-62. Epub 2010 Apr 9. PubMed PMID: 20382242.
26. Negri DR, Bona R, Michelini Z, Leone P, Macchia I, Klotman ME, **Salvatore M**, Cara A. Transduction of human antigen-presenting cells with integrase-defective lentiviral vector enables functional expansion of primed antigen-specific CD8(+) T cells. *Hum Gene Ther*. 2010 Aug;21(8):1029-35. PubMed PMID: 20210625.
27. Fontana JM, Alexander E, **Salvatore M**. Translational research in infectious disease: current paradigms and challenges ahead. *Transl Res*. 2012 Jun;159(6):430-53. Epub 2012 Jan 15. Review. PubMed PMID: 22633095.
28. Fontana JM, Christos PJ, Michelini Z, Negri D, Cara A, **Salvatore M**. Mucosal immunization with integrase-defective lentiviral vectors protects against influenza virus challenge in mice. *PLoS One*. 2014;9(5):e97270. eCollection 2014. PubMed PMID: 24824623.
29. **Salvatore M**, Cara A. Anchoring IDLV: enhanced vectors for immunization. *Nucleic Acid Research*; 2014 2(7):e53.
30. Moroz E, Albrecht RA, Aden B, Beeder AB, Yuan J, García-Sastre A, Edlin BR, **Salvatore M**. Active opioid use does not attenuate the humoral responses to inactivated influenza vaccine. *Vaccine*. 2016 Mar 8;34(11):1363-9. Epub 2016 Feb 6. PubMed PMID: 26859239.
31. **Salvatore M***, Satlin MJ, Jacobs SE, Jenkins SG, Schuetz AN, Moss RB, Van Besien K, Shore T, Soave R. DAS181 for Treatment of Parainfluenza Virus Infections in Hematopoietic Stem Cell Transplant Recipients at a Single Center. *Biol Blood Marrow Transplant*. 2016 May;22(5):965-70. Epub 2016 Feb 22. PubMed PMID: 26904972. ***Corresponding author**
32. Zhou B, Deng YM, Barnes JR, Sessions OM, Chou TW, Wilson M, Stark TJ, Volk M, Spirason N, Halpin RA, Kamaraj US, Ding T, Stockwell TB, **Salvatore M**, Ghedin E, Barr IG, Wentworth DE. Multiplex Reverse Transcription-PCR for Simultaneous Surveillance of Influenza A and B Viruses. *J Clin Microbiol*. 2017 Dec;55(12):3492-3501. PubMed PMID: 28978683.
33. Gallinaro A, Borghi M, Bona R, Grasso F, Calzoletti L, Palladino L, Cecchetti S, Vescio MF, Macchia D, Morante V, Canitano A, Temperton N, Castrucci MR, **Salvatore M**, Michelini Z, Cara A, Negri D. Integrase Defective Lentiviral Vector as a Vaccine Platform for Delivering Influenza Antigens. *Front Immunol*. 2018;9:171. eCollection 2018. PubMed PMID: 29459873.
34. Ding T, Song T, Zhou B, Geber A, Ma Y, Zhang L, Volk M, Kapadia SN, Jenkins SG, **Salvatore M***, Ghedin E*. Microbial Composition of the Human Nasopharynx Varies According to Influenza Virus Type and Vaccination Status. *mBio*. 2019 Jul 2;10(4). PubMed PMID: 31266874. ***Co-corresponding author**
35. Kodiyanplakkal RPL, Laplante JM, Westblade LF, van Besien K, **Salvatore M**, St George K. Detection and Characterization of Influenza B Virus With Reduced Neuraminidase Susceptibility in a Stem Cell Transplant Recipient. *Open Forum Infect Dis*. 2019 Dec;6(12):ofz493. doi: 10.1093/ofid/ofz493. eCollection 2019 Dec. PubMed PMID: 32128335.

36. Maldarelli GA, Savage M, Mazur S, Oxford-Horrey C, **Salvatore M**, Marks KM. Remdesivir Treatment for Severe COVID-19 in Third-Trimester Pregnancy: Case Report and Management Discussion. *Open Forum Infect Dis*. 2020 Sep;7(9):ofaa345. PubMed PMID: 32934969.
37. **Salvatore M***, Laplante JM, Soave R, Orfali N, Plate M, van Besien K, St George K. Baloxavir for the treatment of Influenza in allogeneic hematopoietic stem cell transplant recipients previously treated with oseltamivir. *Transpl Infect Dis*. 2020 Aug;22(4):e13336. Epub 2020 Jun 10. PubMed PMID: 32449254. ***Corresponding author**
38. Michelini Z, Minkoff JM, Yang J, Negri D, Cara A, Hanson BJ, **Salvatore M**. Integrase-Defective Lentiviral Vectors for Delivery of Monoclonal Antibodies against Influenza. *Viruses*. 2020 Dec 17;12(12). PubMed PMID: 33348840.
39. Rendeiro AF, Casano J, Vorkas CK, Singh H, Morales A, DeSimone RA, Ellsworth GB, Soave R, Kapadia SN, Saito K, Brown CD, Hsu J, Kyriakides C, Chiu S, Cappelli LV, Cacciapuoti MT, Tam W, Galluzzi L, Simonson PD, Elemento O, **Salvatore M***, Inghirami G*. Profiling of immune dysfunction in COVID-19 patients allows early prediction of disease progression. *Life Sci Alliance*. 2021 Feb;4(2). Print 2021 Feb. PubMed PMID: 33361110. ***Co-senior, co-corresponding author**
40. Butler D, Mozsary C, [...], **Salvatore M**, Loda M, Westblade LF, Cushing M, Wu S, Levy S, Chiu C, Schwartz RE, Tatonetti N, Rennert H, Imielinski M, Mason CE. Shotgun transcriptome, spatial omics, and isothermal profiling of SARS-CoV-2 infection reveals unique host responses, viral diversification, and drug interactions. *Nat Commun*. 2021 Mar 12;12(1):1660. PubMed PMID: 33712587.
41. Mathad JS, Lee MH, Chalem A, Frey MK, Chapman-Davis E, Kopparam RV, Dayal AK, Wald G, Pinheiro LC, Satlin MJ, Goyal P, Safford MM, **Salvatore M***, Holcomb K*. Sex differences in Covid-19 presentation and outcomes in New York City: A cohort study. *Open Forum Infect Dis*. 2021 Jul 9;8(8):ofab370. PMID: 34381847 ***Equal contribution**
42. Rathnasinghe R, **Salvatore M**, Zheng H, Jangra S, Kehrer T, Mena I, Schotsaert M, Muster T, Palese P, García-Sastre A. Interferon mediated prophylactic protection against respiratory viruses conferred by a prototype live attenuated influenza virus vaccine lacking non-structural protein 1. 2021 *Sci Rep* 11, 22164. PMID 34401874 <https://doi.org/10.1038/s41598-021-01780-8>
43. Rendeiro AF, Vorkas CK, Krumsiek J, Singh H, Shashi Kapatia S, Cappelli LV, Cacciapuoti MT, Inghirami G, Elemento E, **Salvatore M**. Metabolic and immune markers for precise monitoring of COVID-19 severity and treatment. *Front Immunol*, 12 January 2022 | <https://doi.org/10.3389/fimmu.2021.809937>
44. Park J, Foox J, Hether T, [...] **Salvatore M**, Loda M, Westblade LF, Cushing M, Rennert H, Kriegel AJ, Elemento O, Imielinski M, Borczuk AC, Meydan C, Schwartz RE, Mason CE. System-wide loss of tissue identity in COVID-19 patients. *Cell Reports Medicine*, 2022, 1;24, 100522
45. Mzava O, Pellan [...] **Salvatore M**, Satlin M, Suthanthiran M, Lee J, Mason CE, Dadhania D, De Vlaminc I. A metagenomic DNA sequencing assay that is robust against environmental DNA contamination. *Nat Commun* 2022, 13: 4197
46. Wang C, Honce R, **Salvatore M.**, D. Chow, D. Randazzo, Yang J, Twells NM, Mahal LK, Schultz-Cherry S and Ghedin E. Reduced inflammatory response and promoted multiciliated cell differentiation in mice protected by defective interfering influenza virus. *J Virol* 2023, 97: 6.
47. Chen C, Parthasarathy, S, Leung, J, Wu, M; Drake, K; Ridaura, V; Zisser, H; Conrad, W; Tapson, V; Moy, J; deFilippi, C; Rosas, I; Prabhakar, B; Basit, M; **Salvatore, M**, Krishnan, J; Kim, C. Distinct temporal trajectories and risk factors for Post-acute sequelae of SARS-CoV-2 infection. *Front Med* 2023 Oct 16;10:1227883 eCollection 2023.
48. Drake KA, Talantov D, Tong GJ, Lin JT, Verheijden S, Katz S, Leung JK, PRESCO Study Group. Multi-omic Profiling Reveals Early Immunological Indicators for Identifying COVID-19 Progressors. *Clin Immunol*. 2023 Nov;256:109808. doi: 10.1016/j.clim.2023.109808. Epub 2023 Oct 16.
49. Xu C, Wang A, Ebrahim L, Sullivan L, Tasker C, Pizutelli V, Couret J, Hernandez C, Kolli P, Deb PQ, Fritzky L, Subbian S, Gao N, Lo Y, **Salvatore M**, Rivera A, Lemenze A, Fitzgerald-Bocarsly

P, Tyagi S, Lu W, Beaulieu A, Chang TL. Interferon ϵ restricts Zika virus infection in the female reproductive tract. *PNAS Nexus*. 2023 Oct 25;2(11):pgad350.

50. Kusakabe T, Lin WY, Cheong JG, Singh G, Ravishankar A, Yeung ST, Mesko M, DeCelie MB, Carriche G, Zhao Z, Rand S, Doron I, Putzel GG, Worgall S, Cushing M, Westblade L, Inghirami G, Parkhurst CN, Guo CJ, Schotsaert M, García-Sastre A, Josefowicz SZ, **Salvatore M**, Iliev ID. Fungal microbiota sustains lasting immune activation of neutrophils and their progenitors in severe COVID-19. *Nat Immunol*. 2023 Nov;24(11):1879-1889. Epub 2023 Oct 23.
51. Early immune factors associated with the development of post-acute sequelae of SARS-CoV-2 infection in hospitalized and non-hospitalized individuals JM Leung, MJ Wu, P Kheradpour, VK Ridaura, J Allen, C Parsy-Kowalska, VF Tapson, JN Moy, CR deFilippi, JA Krishnan, BS Prabhakar, **M Salvatore**, CC Kim *Frontiers in Immunology* 15, 1348041
52. Nooruzzaman M, Johnson KEE, Rani R, Finkelsztejn EJ, Caserta LC, Kodiyanplakkal RP, Wang W, Hsu J, Salpietro MT, Banakis S, Albert J, Westblade L, Zanettini C, Marchionni L, Soave R, Ghedin E, Diel DG, **Salvatore M**. Emergence of transmissible SARS-CoV-2 variants with decreased sensitivity to antivirals in immunocompromised patients with persistent infections. *Nat Commun* 15, 7999 (2024). <https://doi.org/10.1038/s41467-024-51924-3>

b. Reviews and Editorials

1. **Salvatore M**, Pocchiari M. Biocontaminazione da virus lenti non-convenzionali. *Proceedings of the V National Congress of the Association for the Study and Control of the Ambiental Pollution*. 1991; 165-186.
2. **Salvatore M**, Garcia-Sastre A. Virus versus host: modulation of the host a/b interferon pathway by the influenza A virus NS1 protein. *International Congress Series*. 2001; 1219:513-520.

c. Book Chapters

1. Manna, R., **Salvatore, M**. Gammopatie monoclonali e policlonali. in: *Manuale di immunologia clinica*. Nuova Italia Scientifica ed.1990; 9:101-105.
2. **Salvatore, M.**, Manna, R. Le immunodeficienze. in: *Manuale di immunologia clinica*. Nuova Italia Scientifica ed. 1990; 10: 107-118
3. Ghirlanda G, Manna R, **Salvatore M**, Greco AV. Prediction of type 1 diabetes: the Rome family study. In: *Immunotherapy of type 1 diabetes*. Andreani D, Kolb H, Pozzilli P, editors. New York: John Wiley & Sons; 1989. p.177-184.
4. **Salvatore M**, Meyers B. Metronidazole. In: *Principles and Practice of Infectious Diseases*. 8th ed. Mandell G, Douglas J, Bennett J, editors. Philadelphia: Churchill Livingstone; 2009. Chapter 29.
5. Meyers B. **Salvatore M**. Tetracyclines and Chloramphenicol. In: *Principles and Practice of Infectious Diseases*. 7th ed. Mandell G, Douglas J, Bennett JR, editors. Philadelphia: Churchill Livingstone; 2009. Chapter 27.
6. Meyers, B., **Salvatore, M**. Aseptic Meningitis Syndrome. In D. Schlossberg (Ed.), *Clinical Infectious Disease*. 2008; 513-520. Cambridge: Cambridge University Press. doi:10.1017/CBO9780511722240.075
7. Fontana JF, Eiras D, **Salvatore M**. Human Influenza Virus Infections. In: *Human Respiratory Viral Infections*. Sing SK, editor. Boca Raton, FL: CRC press Group; 2014. p.404-436

d. Manuscripts submitted/under revision

1. Ali R, Sule G , Lu C, Carmona-Rivera C, Lucotti S, Wu Q , Campbell PL, Gurrea Rubio, Fox S, Brodie , Mattichak M, Tambralli A , Yalavarthi, Ikari Y, Zuo WY, Imberti L, Caruso A , Caccuri F, Quaresima V, Sottini A, Kuhns D , Fink D , Castagnoli R, Delmonte O, Kenney H, Zhang Y, Magliocco M, Su H , Notarangelo L, Zemans R, Mao-Draayer Y , Matei I, **Salvatore M**, Lyden D,

Kanthi Y, Kaplan M, Knight J, Fox D. Identification of CD13 and Its Soluble Form as Potential Mediators for Neutrophil-Induced Hyperinflammation and Thrombosis in SARS-CoV-2 Infection. *Under revision*

2. Clement CC, Rossini S, Volpi C, Shetty M, Rusinova R, Aitziber B, Galluzzi, Giorgio Inghirami, **Salvatore M**, Caielli S, Pascual V, Lu T, L, D'Alessandro A, Soni R, Mota I, Guerin D, Orabona C, Yano H, Nguyen AM, Kumar S, Santambrogio. The biogenic amine 3HKA restrains inflammation via non-canonical AhR signaling *Under revision*

e. Manuscripts in Preparation

3. Manohar J, Abedian S, Martini R, Kulm S, **Salvatore M**, Ho K, Christos P, Campion T, Imperato-McGinley J, Ibrahim S, Evering TH, Phillips E, Tamimi R, Bea V, D Balogun O, Sboner A, Elemento O, Davis MB. Social and Clinical Determinants of COVID-19 Outcomes: Modeling Real-World Data from a Pandemic Epicenter. medRxiv. 2021 Apr 7. doi: 10.1101/2021.04.06.21254728. PubMed PMID: 33851193.
1. Michelini Z, Minkoff JM, Yang J, Cara, A, **Salvatore, M**. Intranasal administration of multi-antigen IDLV protect from homologous and heterosubtypical influenza challenge in mice (presented as a poster at: Options X for the Control of Influenza Singapore August 2019)
2. Chernak, B, Coskun E, Cooley V, Pao K, Soave R, Van Basin K, Shore T, **Salvatore M**. Clinical Characteristics and risk factors for adverse outcome of influenza infections in hematopoietic stem cell transplants
3. Ding T, Song T, Zhou B, Geber A, Ma Y, Satlin M, Soave RM, Jenkins S, Ghedin E, **Salvatore M**. Longitudinal of the respiratory microbiome in hematopoietic stem transplant recipient with respiratory viral infections.